netFormulary
 Report : A-Z of formulary items 26/05/2020 22:34:49
[Back]
 
Section Name Details
19 Actico® cohesive bandage

10cm x 6m

 

Atico Web Page with directions for use

19 K-Soft sub-compression wadding

10cm x 4.5m

05.03.01 Abacavir Ziagen®
  • Ziagen® Tablets film-coated 300mg
  • Ziagen® Oral solution sugar free, 20mg/mL
05.03.01 Abacavir and Lamivudine 

Abacavir 600mg / lamivudine 300mg (Kivexa®) Tablet film-coated

10.01.03 Abatacept Orencia®

Orencia Intravenous infusion 250mg

08.01.05 Abemaciclib Verzenios®

Tablet 150mg

 

08.03.04.02 Abiraterone Zytiga®

Zytiga® Tablets 500mg

 

06.01.02.03 Acarbose Glucobay®

Tablets 50mg, 100mg

 

Note: Acarbose should be taken or chewed with the first mouthful of food or swallowed whole with liquid immediately before food. The possibility of GI side effects is reduced by lower incremental dosage increases

11.06 Acetazolamide Diamox®
  • Tablets 250mg
  • Diamox®  Modified Release Capsules 250mg
  • Injection 500mg (Hospital only)

Notes: 

  • Acetazolamide is used as parenteral or oral therapy for acute glaucoma.
  • Its side effects include paraesthesia, general malaise/fatigue, dizziness, electrolyte imbalance and depression.
12.01.01 Acetic Acid 2% Earcalm®

Ear spray 2% 

11.08.02 Acetylcholine Chloride Miochol-E®
  • Ilube® 5% eye drops
  • 10% eye drops (preservative-free bottle); Unlicensed, Pending supplier

Injection 1%   

 

03.07 Acetylcysteine 

Nacsys® Effervescent Tablets 600mg

Notes:

Mucolytic therapy - Consider in people with a chronic productive cough and only continue use if symptoms improve. Do not routinely use to prevent exacerbations.

11.08.01 Acetylcysteine  Ilube®
  • Ilube® 5% eye drops
  • 10% eye drops (preservative-free bottle); Unlicensed, Pending supplier

Notes:

  • For hospital specialist initiation in dry eye conditions assoiciated with mucus produ
05.03.02.01 Aciclovir 
  • Tablets, Sugar Free 200mg, 400mg, 800mg
  • Oral Suspension, Sugar Free 200mg/5mL, 400mg/5mL
  • Intravenous infusion 250mg, 500mg, 1g vials (Hospital only, Red)

Note:

Aciclovir is first line on the basis of evidence and cost.

In shingles, especially where there is ocular or sacral involvement, benefit is greatest in patients over 50. Treatment is only effective if started within 48 hours of rash developing.

Primary Care Healthcare Professionals should refer all cases of opthalmic
shingles to emergency care.

13.10.03 Aciclovir Zovirax®
  • Cream 5%        

 Notes: 

  • Aciclovir cream is licensed for the treatment of initial and recurrent labial and genital herpes simplex infection. Systemic treatment is necessary for buccal or vaginal infections.
  • Treatment should begin when the patient is symptomatic (pro-dromal phase) i.e. tingling, but once there is any evidence of a lesion, evidence shows that aciclovir is only as effective as a base cream.
  • Should not be prescribed in Primary Care or at Discharge for herpes simplex virus infections of the lips.
  • Advise patient to purchase.
11.03.03 Aciclovir eye ointment 3% Zovirax®

Aciclovir may be used for dendritic corneal ulcers caused by herpes simplex. It may also be used in shingles as an adjunct to full dose oral therapy where there is ophthalmic involvement

13.05.02 Acitretin Neotigason®

Capsules 10mg, 25mg     

Note: 

  • For hospital dermatology specialist use only
03.01.02 Aclidinium Eklira Genuair®

Inhalation powder, 375 micrograms (≡ aclidinium 322 micrograms)/inhalation (delivered dose).

DPI - Dry Powder Inhaler

03.01.04 Aclidinium and formoterol inhaler 

Please follow COPD Inhaler Device Pathway in the appendix to help maintain device consistency and follow associated pathway in a step wise approach.

Duaklir Genuair®

340mcg aclidinium/12mcg formoterol (DPI - Dry powder inhaler)

19.01 Actico® 

Cohesive bandage 10cm x 6m

Actico product web site

01.05.03 Adalimumab 
  • Imraldi - Injection 40mg/0.8mL prefilled pen or prefilled syringe
  • Amgevita - Injection 20mg/0.4mL, injection 40mg/0.8mL prefilled pen or prefilled syringe
  • Humira - Injection 40mg/0.4mL, injection 80mg/0.8mL prefilled pen or prefilled syringe
  • Humira - Injection 20mg/0.2mL pre-filled syringe, injection 40mg/0.8mL solution in vial for first line use in paediatrics

Notes:

  • To be prescribed by brand.
  1. First line brand in adults = Imraldi®
  2. Second line brand in adults = Amgevita®
  3. Third line brand in adults = Humira®
  • Hulio and Hyrimoz are non-formulary within Milton Keynes Healthcare.
10.01.03 Adalimumab 
  • Imraldi, Injection, 40mg/0.8mL prefilled pen or prefilled syringe
  • Amgevita, Injection, 20mg/0.4mL; 40mg/0.8mL prefilled pen or prefilled syringe
  • Humira, Injection, 40mg/0.4mL; 80mg/0.8mL prefilled pen or prefilled syringe
  • Humira, Injection, 20mg/0.2mL pre-filled syringe, 40mg/0.8mL solution in vial for first line use in paediatrics

Notes:
To be prescribed by brand.
1. First line brand in adults = Imraldi®
2. Second line brand in adults = Amgevita®
3. Third line brand in adults = Humira®

Hulio and Hyrimoz are non-formulary within Milton Keynes Healthcare.

11.04.02 Adalimumab  
  • Imraldi, Injection, 40mg/0.8mL prefilled pen or prefilled syringe
  • Amgevita, Injection, 20mg/0.4mL; 40mg/0.8mL prefilled pen or prefilled syringe
  • Humira, Injection, 40mg/0.4mL; 80mg/0.8mL prefilled pen or prefilled syringe
  • Humira, Injection, 20mg/0.2mL pre-filled syringe, 40mg/0.8mL solution in vial for first line use in paediatrics

Notes:

  • To be prescribed by brand.
  1. First line brand in adults = Imraldi®
  2. Second line brand in adults = Amgevita®
  3. Third line brand in adults = Humira®

 

  • Hulio and Hyrimoz are non-formulary within Milton Keynes Healthcare 
13.05.03 Adalimumab 
  • Imraldi, Injection, 40mg/0.8mL prefilled pen or prefilled syringe
  • Amgevita, Injection, 20mg/0.4mL; 40mg/0.8mL prefilled pen or prefilled syringe
  • Humira, Injection, 40mg/0.4mL; 80mg/0.8mL prefilled pen or prefilled syringe
  • Humira, Injection, 20mg/0.2mL pre-filled syringe, 40mg/0.8mL solution in vial for first line use in paediatrics

Notes:

  • To be prescribed by brand.
  • First line brand in adults = Imraldi®
  • Second line brand in adults = Amgevita®
  • Third line brand in adults = Humira®

 

  • Hulio and Hyrimoz are non-formulary within Milton Keynes Healthcare 
13.06.01 Adapalene Differin®

Differin cream 0.1%

Differin Gel 0.1%

13.06.01 Adapalene / Benzoyl Peroxide Epiduo®
  • Adapalene 0.1% & benzoyl peroxide 2.5% Gel
  • Adapalene 0.3% & benzoyl peroxide 2.5% Gel

Notes:

  • First-line
  • Use lower strength for mild to moderate acne
  • Use higher strength for more severe acne

 

09.03 Addiphos® solution 

20 mL vial

05.03.03.01 Adefovir Dipivoxil Hepsera®

Tablets 2mg

02.03.02 Adenosine 

Injection 3mg/mL (2-mL vial) - Hospital only

02.07.03 Adrenaline / Epinephrine 
  • Injection 1 in 1000;        1mL amp;           IM or SC     (1mg/mL)
  • Injection 1 in 10,000;     10mL amp;          IV use       (100 microgram/mL)
  • Minijet 1 in 1000;           1mL IM, 1mL SC disposable syringe  (1mg/mL)
  • Minijet 1 in 10,000;        10mL IV disposable syringe   (100 microgram/mL) 

(Subcutaneous injection not generally recommended.)

Dose of intramuscular injection of adrenaline (epinephrine) for the emergency treatment of anaphylaxis by healthcare professionals:

Age

Dose

Volume of adrenaline 

1 in 1000 (1mg/mL)

Child under 6 years

150 microgram

0.15mL

6-12 years

300 microgram

0.3mL

Adult and child 12-18 years

500 microgram

0.5mL

 

03.04.03 Adrenaline / Epinephrine Minijet® Adrenaline 1 in 1000
03.04.03 Adrenaline / Epinephrine EpiPen®, Emerade®, Anapen®

Emerade®

  • 150 micrograms solution for injection in pre-filled pen 
  • 300 micrograms solution for injection in pre-filled pen 
  • 500 micrograms solution for injection in pre-filled pen  

Epipen®  

  • Auto-injector 300 microgram dose
  • Junior Auto-injector 150 microgram dose

Anapen® 

  • Auto-injector 500 microgram dose

Note:

People who have been prescribed an adrenaline auto-injector because of the risk of anaphylaxis should carry two with them at all times for emergency, on-the-spot use. After every use of an adrenaline auto-injector, an ambulance should be called (even if symptoms are improving), the individual should lie down with their legs raised and, if at all possible, should not be left alone.

02.07.03 Adrenaline / Epinephrine 1 in 10,000 

Injection 1 in 10,000 (100 microgram/mL), 10mL amp - To be diluted

03.01.05 Aerobika® Device

Single patient use medical device.

For airway clearance for patients who produce and retain or cannot easily clear sputum.

Note:

  • This should be initiated and supplied by Specialist Respiratory Physiotherapists only.
  • Not to be prescribed by the GP, however the GP may be asked to refer patients to the Respiratory Physiotherapists to review the patients using the device or to replace lost, damaged or worn out devices.
03.01.05 AeroChamber Plus Flow-Vu Anti-Static® 

1. AeroChamber Plus® Flow-Vu® with small mask for infants (0-18 months) [Orange]
2. AeroChamber Plus® Flow-Vu® with medium mask for children (1-5 years) [Yellow]
3. AeroChamber Plus® Flow-Vu® with youth mouthpiece (5+ years) [Mint Green]
4. AeroChamber Plus® Flow-Vu® Adult mouthpiece [Blue]
5. AeroChamber Plus® Flow-Vu® adult with small mask [Purple]
6. AeroChamber Plus® Flow-Vu® adult with large mask [Blue]

Notes:

One size mask doesn’t fit all – there are now multiple mask sizes to fit patients of different ages (e.g. a small and large adult mask, etc)

 

Spacer device compatible MDI masks available

Volumatic Clenil Modulite, Ventolin, Flixotide, Serevent, Seretide Paediatric

Aerochanber Plus Flow-Vu - All pressurised metered dose inhalers - Infant, child and adult

 
Spacer device Compatible MDI Masks available
AeroChamber Plus® Flow-Vu® All pressurised metered dose inhalers Infant, child and
Adult
Volumatic Clenil Modulite, Ventolin, Flixotide, Serevent, Seretide Paediatric

 

08.01.05 Afatinib Giotrif®

Tablet 20mg, 30mg, 40mg, 50mg

 

08.01.05 Aflibercept Zaltrap®

Solution for infusion 25mg/ml; 4ml and 8ml vials

 

11.08.02 Aflibercept Eylea®

Eylea® Solution for intravitreal injection, 40mg per 1mL vials

20 Ajmaline 

Injection 50mg/10mL

Recommended dose: 1 mg/kg (actual body weight) up to a maximum dose of 100 mg

Note: Ajmaline approved strictly for use in the diagnosis of Brugada syndrome by Consultant Cardiologists only.

08.01.05 Alectinib Alecensa®

Capsules 150mg

 

08.02.03 Alemtuzumab Lemtrada®

Lemtrada® Concentrate for IV infusion 10mg/mL

 

06.06.02 Alendronic Acid 

Tablets 10mg

06.06.02 Alendronic Acid 

Tablets 70mg

06.06.02 Alendronic Acid effervescent Binosto

Tablets 70mg (Binosto)


Notes:
Reserved for patients who have confirmed swallowing difficulties
For hospital initiation only in line with local guideline after failure of standard
Alendronic acid and risedronate.

09.06.04 Alfacalcidol One-Alpha®
  • Capsules 250 nanograms, 500 nanograms, 1 microgram
  • Oral drops 2 microgram in 1mL
  • Injection 2 micrograms 1mL (1mL ampoules)
04.07.02 Alfentanil Rapifen®
  • Injection 500 microgram per 1mL (2mL, 10mL amps)
  • Injection 5mg per 1mL (1mL amps)
  • 1mg in 2mL amp
  • 5mg in 1mL amp intensive care injection

 Note:

    • Intravenous use by anaesthetists and intensive care physicians only due to rapid and profound respiratory depression.
    • Although not included in the original safety alert, the use of 5mg in 1mL amps is subject to the same restrictions as high strength morphine and diamorphine as per NPSA/2006/12.
10.03.02 Algesal 

Cream containing diethylamine salicylate 10%

Should not be prescribed for self-limiting injuries. Patient to be advised to purchase over the counter.

02.12 Alirocumab Praluent®
  • 75mg solution for injection in pre-filled pen, pre-filled syringe
  • 150mg solution for injection in pre-filled pen
13.05.01 Alitretinoin Toctino®

Capsules 10mg, 30mg 

Notes: 

19.01 Allevyn Gentle Border 

8.6cm x 7.7cm Oval

Allevyn product web site

10.01.04 Allopurinol 

Tablets 100mg, 300mg

Notes:

  • Allopurinol is indicated for gout prophylaxis but it should never be started
    during, or within one month of, an acute attack.
  • Colchicine or NSAIDs should be used as a prophylactic and continued for at least one month after the hyperuricaemia has been corrected.
  • The dose of allopurinol and colchicine should be reduced in patients with renal failure.
09.06.05 Alpha Tocopheryl Acetate 

Suspension 500mg in 5ml

07.04.05 Alprostadil Caverject®

Intracavernosal injection 10 microgram, 20 microgram, 40 microgram

1. Full information is in the Drug Tariff Part XVIIIB Prescriptions must be endorsed SLS. A prescription not containing this endorsement will not be reimbursed by the Prescription Pricing Division and so should not be dispensed.
2. HSC 1999/177 recommends that treatment for impotence should be available from specialist services when impotence is causing severe distress. Patients who are prescribed treatment for impotence on the NHS following the guidance in this circular need to continue to receive their treatment through specialist
services. GPs cannot issue an FP10, endorsed SLS, where treatment has been started by a specialist for a patient suffering severe distress unless they also meet one of the above criteria.
3. Patients who are not eligible for an NHS prescription can be issued a private prescription.
4. HSC 1999/148 advises doctors that one treatment a week will be appropriate for most patients treated for erectile dysfunction. If a GP exercising his clinical judgement considers that more than one treatment a week is appropriate he should prescribe that amount on the NHS.

01.01.01 Altacite plus 
02.10.02 Alteplase 

Injection 20mg, 50mg vial 

 

20 ALUMINIUM ACETATE 8% ear drops 
  • Ear drops 8%
  • For ear drops 8% - dilute 8 parts aluminium acetate ear drops (13%) with 5 parts purified water. Must be freshly prepared
04.09.01 Amantadine 
  • Capsules 100mg
  • Syrup 50mg in 5mL  
10.02.01 Amifampridine Firdapse

Tablets 10mg

05.01.04 Amikacin 

Injection 100mg/2mL, 500mg/2mL

Note:

Amikacin is included for resistant infections under Consultant Microbiologist's recommendation

02.02.03 Amiloride hydrochloride 
  • Tablets 5mg
  • Oral solution - sugar free 5mg/5mL  
03.01.03 Aminophylline Phyllocontin Continus®

Phyllocontin Continus®

Modified release tablets 225mg 

03.01.03 Aminophylline IV 

Injection 250mg/10mL Min-I-Jet (Hospital only)

02.03.02 Amiodarone 
  • Tablets 100mg, 200mg
  • Injection 30mg/mL (10-mL amp - Pre-filled syringe)
  • Infusion - Sterile concentrate 50mg/mL (3-mL amp)

Notes:

  • Amiodarone has a very long half-life (extending to several weeks).
  • Amiodarone usual oral loading dose regime, 200mg TDS for 1 week then BD for a further week. Maintenance doses, usually 200mg OD or minimum required to control the arrhythmia.
  • Monitoring of patients taking amiodarone is required; LFT & TFT should be done 6-monthly and 12 months after stopping treatment.
  • Please refer to the BNF or product SPC for further requirements.
  • There are significant drug interactions with amiodarone, including digoxin and warfarin. 
04.02.01 Amisulpride 

 Tablets 50mg, 100mg, 200mg, 400mg

04.03.01 Amitriptyline 
  • Tablets 10mg, 25mg, 50mg
  • Oral solution 25mg in 5mL and 50mg in 5mL
04.07.03 Amitriptyline 

Tablets 10mg, 25mg, 50mg

04.07.04.02 Amitriptyline 

(Off-label indication)

  • Tablets 10mg, 25mg, 50mg
  • Oral solution 50mg/5ml
02.06.02 Amlodipine 

Tablets 5mg, 10mg

13.10.02 Amorolfine Loceryl®

5% nail lacquer, 5mL

Notes:

  • Review every three months
05.01.01.03 Amoxicillin 

Capsules 250mg, 500mg

Oral sachet 3 gram

Oral suspension sugar free 125mg/5ml, 250mg/5ml

Injection 250mg, 500mg, 1 gram

05.02 Amphotericin  AmBisome®

AmBisome® Intravenous Infusion, powder for reconstitution, 50mg vials

Note:

Liposomal amphotericin is reserved only for patients where toxicity is a problem.

Fungizone should be used first line in most patients.

 

Advice for healthcare professionals:
• When prescribing, communicating and dispensing amphotericin products, use both the complete genericname and the proprietary name:
o non-lipid amphotericin (Fungizone)
o liposomal amphotericin (AmBisome)
o lipid-complex amphotericin (Abelcet)
• Verify the product name and dose before administration, especially if the dose prescribed exceeds 1·5 mg/kg—the maximum recommended dose for Fungizone.

Report suspected adverse reactions associated with amphotericin B, including medication error with associated harm to patients, on a Yellow Card.

05.02 Amphotericin (non-lipid) Fungizone®

Intravenous infusion, powder for reconstitution 50mg vials

Note:

Fungizone® should be used first line in most patients.

Advice for healthcare professionals:
• When prescribing, communicating and dispensing amphotericin products, use both the complete generic name and the proprietary name:
o non-lipid amphotericin (Fungizone)
o liposomal amphotericin (AmBisome)
o lipid-complex amphotericin (Abelcet)
• Verify the product name and dose before administration, especially if the dose prescribed exceeds 1·5 mg/kg—the maximum recommended dose for Fungizone.

08.01.05 Amsacrine Amsidine®

Concentrate for IV infusion 75mg in 1.5mL

09.01.04 Anagrelide 

Capsules 500 micrograms 

08.03.04.01 Anastrozole 

Tablets 1mg

 

14.05.03 Anti-D (Rh0) Immunoglobulin 
  • Refer to Trust Guidelines for the use of Anti-D immunoglobulin in pregnancy
  • Pharmacy do not stock this product. Supplies are available from MKUH Blood Bank section within Pathology (Ext 85776)
01.07.02 Anusol® 

Cream

Notes: 

  • Should not be prescribed in Primary Care or at Discharge.
  • Advise patient to purchase, unless prescription is for long-term regular use.
01.07.02 Anusol-HC® 

Ointment and Suppositories 

Notes: 

  • Should not be prescribed in Primary Care or at Discharge.
  • Advise patient to purchase, unless prescription is for long-term regular use.
02.08.02 Apixaban Eliquis®

Tablets 2.5mg, 5mg 

 

04.09.01 Apomorphine 
  • APO-go PEN 10mg/ml; 3ml Pen Injector
  • APO-go PFS 5mg/ml; 10ml prefilled syringe
  • APO-go 10mg/ml ampoules; 2ml and 5ml amps

Note:  See Shared Care Guideline here

Shared care prescribing guideline. Apomorphine in Parkinson's disease.

11.08.02 Apraclonidine Iopidine®
  • Eye drops 0.5%
  • Single use eye drops 1% 
  • Ophthalmic solution 1%
10.01.03 Apremilast 

Tablets 10mg, 20mg, 30mg

19.01 Aquacel Ag flat 
19.01 Aquacel Ag ribbon 

 

Aquacel Ag ribbon company web site

01.06.03 Arachis Oil 

Enema 130mL

Note: Avoid the use of Arachis oil in patients with a known nut allergy.

04.02.01 Aripiprazole 

Tablets 5mg, 10mg, 15mg, 30mg

 

04.02.02 Aripiprazole Abilify Maintena®

Injection in pre-filled syringes, 400mg powder and solvent for prolonged-release suspension for injection.

Notes:

  • Restrictions on the use of Aripiprazole prolonged – release injection
    1) Can only be initiated by a consultant psychiatrist AND
    2) Can only be initiated for a patient who has a diagnosis of schizophrenia AND
    3) Should only be initiated for patients where a “typical” depot has been considered and cannot be used i.e. it is not clinically appropriate or tolerated. One of the typical antipsychotic depots should be considered first due to the significant financial implications. AND
    4) Can only be initiated for patients who have a documented  clinical response to treatment doses of aripiprazole, tolerated it, and would be considered mentally “stable” with this antipsychotic as monotherapy AND
    5) Follow the approval process for initiation (form to be completed acknowledging the above details)
08.01.05 Arsenic Trioxide Trisenox®

Trisenox® Injection 10mg/10mL concentrate for solution for infusion ampoules

 

05.04.01 Artemether with lumefantrine Riamet®

Tablets 20mg/120mg

20 Artesunate 

Injection 60mg

Alternative reserved for 2nd line treatment ONLY in the following cases , following the advice of consultant in Infectious diseases -

  • Contraindications to Quinine
  • Very severe disease (parasite count > 20% )
  • Deterioration on optimal doses of Quinine
  • Cardiovascular disease that increases the risks from Qunine - Patients with Falciparum malaria from SE Asia where relative Quinine resistance is most likely
12.03.05 Artificial Saliva Spray  Orthana®

Aerosol spray  

09.06.03 Ascorbic Acid Vitamin C

Tablets 50mg, 100mg, 500mg

Notes:

  • Should not be prescribed in Primary Care or at Discharge.
  • Advise patient to purchase, unless prescription is for long-term regular use.
  • Deficiency is rare and ascorbic acid is not recommended.
  • In iron deficiency states ascorbic acid may increase gastro-intestinal iron absorption but its role in clinical practice is not established.
01.01.01 Asilone 
02.09 Aspirin 
  • Dispersible tablets 75mg, 300mg
  • Enteric-coated tablets 75mg, 300mg
04.07.01 Aspirin 
  • Dispersible tablets 75mg, 300mg
05.03.01 Atazanavir Reyataz®

Capsules 150mg, 200mg, 300mg

05.03.01 Atazanavir sulfate and cobicistat Evotaz®

Evotaz® Tablets 300mg/150mg

02.04 Atenolol 
  • Tablets 25mg, 50mg, 100mg
  • Syrup - Sugar free 25mg/5mL
  • Injection 5mg/10mL (Hospital only)
08.01.05 Atezolizumab Tecentriq®

Tecentriq® 1,200mg concentrate for solution for infusion in vials

 

04.04 Atomoxetine Strattera®

Capsules 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg 

 

02.12 Atorvastatin 

Tablets 10mg, 20mg, 40mg, 80mg

07.01.03 Atosiban 

Injection 7.5mg/mL (0.9mL vial)
Concentrate for IV infusion 7.5mg/mL (5mL vial)

Notes:
Atosiban is included for use second line if the patient has side effects with
beta2-agonists

For termination of pregnancy, a single dose of mifepristone is followed by
administration of a prostaglandin (gemeprost or misoprostol [unlicensed]).

Guidelines from the Royal College of Obstetricians and Gynaecologists; The
Care of Women Requesting Induced Abortion (November 2011) include the
following [unlicensed] regimens for inducing medical abortion as detailed in the
BNF:

15.01.05 Atracurium 
  • 25mg in 2.5mL amp
  • 50mg in 5mL amp
  • 250mg in 25mL vial
11.05 Atropine 
  • Eye drops 1%  Contains: benzalkonium chloride (Amber 1)
  • Minims® Single use unit dose eye drops 1% (Amber 3)

Notes:

  • Atropine has long activity, sometimes up to a week.
  • It is used to treat anterior uveitis to prevent posterior synechiae.
  • Atropine has a tendency to cause hypersensitivity.
  • Atropine Minims® single use eye drops are also recommended for sublingual use in patients with sialorrhea in Parkinson’s Disease; Consultant neurologist initiation and stabilisation only.

 

15.01.03 Atropine Sulphate 

600 micrograms in 1ml amp (Hospital Only)

  • 1mg in 5ml PFS
  • 3mg in 10ml PFS
  • 600 micrograms in 1ml PFS
  • 1mg in 10ml Min-I-Jet
  • 3mg in 30ml Min-I-Jet
  • 500 micrograms 5ml Min-I-Jet

     

08.02.03 Avelumab Bavencio®

Bavencio® 20mg/mL concentrate for solution for infusion vials

 

08.02.04 Axicabtagene ciloleucel YESCARTA®

Single dose intravenous infusion

 

 

08.01.05 Axitinib Inlyta®

Inlyta® Tablet 1mg, 3mg, 5mg, 7mg

 

08.01.03 Azacitidine Vidaza®

Injection, powder for reconstitution 100mg vial

 

01.05.03 Azathioprine 

Tablets 25mg, 50mg

Tablets 10mg - available on named-patient basis only

Notes:

  • Avoid concomitant use of azathioprine with allopurinol, unless supervised by an appropriate specialist.
08.02.01 Azathioprine 

Tablets 25mg, 50mg

tablets 10mg - available on named-patient basis only

Avoid concomitant use of azathioptine with allopurinol, unless supervised by an appropriate specialist.

Monitoring of azathioprine is essential.

10.01.03 Azathioprine 

Tablets 25mg, 50mg

13.05.03 Azathioprine 
  • Tablets 25mg, 50mg
  • Tablets 10mg - available on named-patient basis only  
13.06.01 Azelaic Acid Finacae®

1 g Finacea Gel contains 150 mg (15%) azelaic acid.

13.06.01 Azelaic Acid Skinoren®

1 g of Skinoren Cream contains 200 mg (20% w/w) azelaic acid.

12.02.01 Azelastine and fluticasone Dymista

 Fluticasone proprionate with azelastine hydrochloride as Dymista®  Nasal spray 

Notes: 

  • 2nd line to oral antihistamine and Avamys® nasal spray following at least a month's trial of topical corticosteroid
05.01.05 Azithromycin 
  • Capsules 250mg
  • Tablets 250mg, 500mg
05.01.02.03 Aztreonam Azactam®

Powder and solvent for nebuliser solution 75mg

10.02.02 Baclofen 
  • Tablets 10mg
  • Liquid sugar free 5mg in 5ml
10.01.03 Baricitinib Olumiant®

Olumiant® Tablets film-coated 2mg, 4mg

08.02.02 Basiliximab Simulect®

Simulect Injection 10mg, 20mg

 

 

08.02.04 BCG bladder instillation 

Bacillus Calmette-Guérin
ImmuCyst® bladder instillation 81mg vial
OncoTICE® bladder instillation 12.5mg vial

14.04 BCG vaccine diagnostic agent 

Injection, 20 units/ml (2 units/0.1ml dose) - for routine use

Injection, 100 units/ml (10 units/0.1ml dose), 1.5ml vial

Note:

  • Intradermal injection for Mantoux test
  • 100 unit/ml injection is required if first test is negative and a further test is considered appropriate.
14.04 BCG vaccine Intradermal 

Injection (powder for suspension), freeze-dried preparation of live bacteria of a strain derived from the bacillus of Calmette and Guérin.

Note:

  • This is an intradermal vaccine.
  • This SSI vaccine must be suspended with 1ml of the Diluted Sauton SSI solvent only.
06.01.01.03 BD Viva 
03.02 Beclometasone Clenil Modulite®

Clenil Modulite® MDI 50, 100, 200, 250 micrograms/dose

Inhaled Cortocosteroids (ICS) Important notes:

The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar.

03.02 Beclometasone Qvar®

Qvar® MDI 50, 100 micrograms/dose

Qvar® 50, 100 micrograms/dose  Easi-Breathe & Autohaler (DPIs)

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar.

Notes:

Qvar® has extra-fine particles, is more potent than traditional beclometasone dipropionate CFC-containing inhalers and is approximately twice as potent as Clenil Modulite®.

Qvar® is only licensed for children over 12.

The dose of Qvar will need adjusting when transferring a patient with well controlled asthma from other beclometasone inhalers.

Initially a 100 microgram metered dose of Qvar should be prescribed for:
200 - 250 micrograms of beclometasone dipropionate or budesonide
100 micrograms of fluticasone propionate

03.02 Beclometasone Easyhaler®

Easyhaler Beclometasone 200micrograms/dose dry powder inhaler 

Easyhaler® Beclometasone Dipropionate is not licensed for use in children under 18 years.

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar.

03.02 Beclometasone and formoterol Fostair®

MDI (Metered Dose Inhaler)

  • Fostair 100/6 MDI (100mcg Beclometasone / 6mcg Formoterol) - licensed for MART therapy
  • Fostair 200/6 MDI (200mcg Beclometasone / 6mcg Formoterol)

 

NEXThaler DPI (Dry Powder Inhaler)

  • Fostair 100/6 (100mcg Beclometasone / 6mcg  Formoterol) - licensed for MART therapy
  • Fostair 200/6 (200mcg Beclometasone / 6mcg Formoterol)

Under 18 years - not recommended.

MART = Maintenance And Reliever Therapy

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar.

12.02.01 Beclometasone Dipropionate 

 Beconase® Aqueous nasal spray, 50 micrograms per spray

Notes:

  • Patients aged over 18 should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term use
  • There are no published studies showing that any one nasal steroid is more effective than any other. Aqueous sprays tend to cause less irritation.    
  • GPs should prescribe Beconase as the first-line choice therapy for allergic rhinitis and ensure the patient knows how to use their nasal spray effectively.
  • Beclomethasone nasal spray is considered as first line therapy. It is relatively cheap, effective and well tolerated, requiring twice daily administration.
  • Systemic absorption may follow on from any nasal steroid particularly if the doses are high and prolonged.
  • CSM recommends that when children are receiving prolonged treatment with nasal corticosteroids the height of the child should be monitored. If growth is slowed then paediatric referral should be considered.
03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®

Pharmalgen® Bee Venom or Wasp Venom extract; Subcutaneous Injection

 

10.01 Belimumab Benlysta®

Intravenous infusion, powder for reconstitution 120mg, 400mg
vials

08.01.01 Bendamustine Hydrochloride 

Injection 25mg, 100mg vials

 

02.02.01 Bendroflumethiazide 

Tablets 2.5mg, 5mg

03.04.02 Benralizumab Fasenra®

Fasenra® Injection, 30mg/ml pre-filled syringe

 

05.01.01.01 Benzathine Benzylpenicillin  

Injection 2,400,000 units

20 Benzoin Tincture, Compound, BP Friars balsam

Benzoin tincture (Friars' Balsam)

  • Tincture, Compound, BP

Notes:

  • Should not be prescribed in Primary Care or at Discharge
    Advise patient to purchase
13.06.01 Benzoyl Peroxide 5% with Clindamycin 1% Duac® Once Daily

Notes:

  • To be used second-line after Epiduo

 

12.03.01 Benzydamine Difflam®
  • Difflam oral rinse 0.15%
  • Difflam® spray 0.15%     

Notes:

  • Benzydamine is useful to treat discomfort in a variety of ulcerative conditions. It may cause stinging, often reduced by dilution with an equal volume of water.
05.01.01.01 Benzylpenicillin Sodium 

Injection 600mg, 1.2g

03.05.02 Beractant Survanta®

Beractant (bovine lung extract) suspensionproviding phospholipid 25mg/ml with lipids and proteins,  8ml vial = 200mg

04.06 Betahistine 

 Tablet 8mg, 16mg

Notes:

  • Vertigo and nausea associated with Ménière’s syndrome and middle ear surgery may be difficult to treat. Hyoscine, antihistamines, and phenothiazines (such as prochlorperazine) are effective in the prophylaxis and treatment of such conditions.
  • Betahistine is licensed solely in treatment of Ménière’s syndrome and prescribers should ensure that betahistine is not being prescribed to treat side effects of other medication.  
06.03.02 Betamethasone Betnesol®

Injection 4mg in 1ml

06.03.02 Betamethasone Betnesol®

Soluble tablets (as sodium phosphate) 500 microgram

11.04.01 Betamethasone Betnesol

Eye ointment: betamethasone 0.1%  

Notes:

  • Inflammation in anterior segment; post-operatively to reduce inflammation following Trabeculectomy
12.01.01 Betamethasone 

Eye/Ear/Nose drops: Betamethasone sodium phosphate 0.1%   

13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic®

Ointment

13.04 Betamethasone (as Valerate) 0.025% Betnovate-RD®
  •   Ointment, 0.025%   
  •  Cream, 0.025%
13.04 Betamethasone (as Valerate) 0.1% Betnovate®
  • Ointment 0.1%
  • Cream: 0.1%  
13.04 Betamethasone (as Valerate) 0.1% with Clioquinol Betnovate-C®
  • Ointment, betamethasone as valerate 0.1% plus clioquinol 3% 
  • cream, betamethasone as valerate 0.1% plus clioquinol 3% 
12.01.01 Betamethasone 0.1% with Neomycin 0.5% ear drops Betnesol N®

 

Ear/Eye/Nose drops: Betamethasone sodium phosphate 0.1%, neomycin sulphate 0.5% 

11.04.01 Betamethasone 0.1% with Neomycin 0.5% eye drops Betnesol N®
  • Eye drops: betamethasone sodium phosphate 0.1%, neomycin sulphate 0.5% 
  • Eye ointment: betamethasone sodium phosphate 0.1%, neomycin sulphate 0.5% 
12.02.03 Betamethasone sodium phoshate 0.1%, neomycin sulphate 0.5% drops Betnesol-N

Drops: Betamethasone sodium phosphate 0.1%, neomycin sulphate 0.5%

Notes:

  • Considered to be a "Drug of Limited Clinical value"
12.02.01 Betamethasone sodium phosphate 

Drops 0.1%

 

Notes:

  • There are no published studies showing that any one nasal steroid is more effective than any other. Aqueous sprays tend to cause less irritation.    
  • GPs should prescribe Beconase as the first-line choice therapy for allergic rhinitis and ensure the patient knows how to use their nasal spray effectively.
  • Beclomethasone nasal spray is considered as first line therapy. It is relatively cheap, effective and well tolerated, requiring twice daily administration.
  • Systemic absorption may follow on from any nasal steroid particularly if the doses are high and prolonged.
  • CSM recommends that when children are receiving prolonged treatment with nasal corticosteroids the height of the child should be monitored. If growth is slowed then paediatric referral should be considered.
08.01.05 Bevacizumab Avastin®

Bevacizumab is recommended for use in wet AMD
Avastin® Concentrate for IV infusion, 25mg in 1mL (100mg/4mL,
400mg/16mL vials)

 

02.12 Bezafibrate 
  • Tablets 200mg
  • Tablets, modified release 400mg 
19.01 Biatain® Silicone Biatain®

7.5 cm x 7.5cm

10cm x10cm

12.5cm x 12.5cm

15cm x 15cm

17.5cm x 17.5cm

10cm x 20cm

10cm x 30cm

15cm x 19cm Sacral

 Biatain company web site

 

08.03.04.02 Bicalutamide 

Tablets 50mg, 150mg

Note:

Casodex® brand is 20 times more expensive than the non-proprietary
Bicalutamide. Please prescribe generically.

Bicalutamide is the only anti-androgen licensed as a single agent for monotherapy in a patient with locally advanced disease. The dosage of bicalutamide is 150mg od as a single agent, or 50mg od when given in conjunction with gonadorelin analogue injection therapy. Care should be take to ensure correct choice of dose.

11.06 Bimatoprost Lumigan®
  • Eye drops 100micrograms/mL [Excipients include: benzalkonium chloride] 
  • Eye drops 300micrograms/mL [Discontinued April 2015]
  • Single-use eye drops 300mcg/mL 

Note: 

Consultant initiation only

11.06 Bimatoprost with Timolol Ganfort®
  • Eye drops, bimatoprost 300mcg/mL, timolol (as maleate) 5mg/mL [Excipients include: benzalkonium chloride] 

 

  • Single-use eye drops, bimatoprost 300micrograms/mL, timolol (as maleate) 5mg/mL    

Note: Consultant initiation only  

08.01.05 Binimetinib 

Tablet 45mg

 

12.03.05 Biotene  Oralbalance®

Dry mouth saliva replacement gel 50g

06.01.01.02 Biphasic Insulin Aspart NovoMix® 30

100 units/ml

06.01.01.02 Biphasic Insulin Lispro Humalog® Mix

Humalog Mix 25, 100 units/ml

Hunalog Mix 50, 100 units/ml

06.01.01.02 Biphasic Isophane Insulin Hypurin® Porcine 30/70 Mix

100 units/ml

06.01.01.02 Biphasic Isophane Insulin Humulin® M3

100 units/ml

06.01.01.02 Biphasic Isophane Insulin Insuman® Comb

Insuman Combo 15, 100 units/ml

Insuman Como 25, 100 units/ml

Insuman Combo 50, 100 units/ml

01.06.02 Bisacodyl 
  • Tablets - Enteric coated 5mg
  • Suppositories 5mg (paediatric), 10mg

Notes:

  • Bisacodyl tablets should not be prescribed in Primary Care or at Discharge for infrequent constipation.
  • Advise patient to purchase, unless prescription is for long-term regular use.
12.02.03 Bismuth and iodoform (BIPP) 

Paste Impregnated Gauze

ENT ONLY

02.04 Bisoprolol 

Tablets 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg

02.08.01 Bivalirudin Angiox®

Injection, powder for reconstitution 250mg vial

Notes:

  • Bivalirudin in combination with aspirin and clopidogrel is recommended for the treatment of adults with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
08.01.02 Bleomycin 

Bleo-Kyowa® 15,000unit powder for solution for injection vials

Note:
Letters sent to healthcare professionals (November 2017)

08.02 Blinatumomab Blincyto®

Blincyto® Powder for concentrate and solution for infusion, 38.5 micrograms in vial

08.01.05 Bortezomib 

Injection 3.5mg

 

08.01.05 Bosutinib Bosulif®

Bosulif® Tablets 100mg, 500mg

 

04.07.04.02 Botulinum Toxin Type A Botox®

Injection 100 unit vial

04.09.03 Botulinum Toxin Type A Dysport®, Botox®, Xeomin®
  • Dysport® Injection 500 unit vial
  • Botox® Injection 100 unit vial
  • Xeomin® Injection 50 unit vial, 100 unit vial 

Notes:

 

Traffic Light Status: Double Red when used for hyperhidrosis and cluster headache. 

Prescribers must seek prior approval from the Individual Funding Request (IFR) panel for use of Botulinum Toxin A in patients with hyperhidrosis and in patients with cluster headache.

04.09.03 Botulinum Toxin Type A Xeomin®

Injection 50 unit vial, 100 unit vial

 

Prescribe by brand - other products are not equivalent

Dysport is more cost effective.

14.04 Botulism antitoxin 

Intravenous infusion

Note:

  • In Pharmacy Emergency Cupboard -Fridge item
08.01.05 Brentuximab vedotin Adcetris®

Adcetris® Injection, 50mg powder for concentrate for solution for infusion in
vial

08.01.05 Brigatinib Alunbrig®

Alunbrig® 30 mg, 90mg, 180mg film coated tablets

 

11.06 Brimonidine Tartrate Alphagan®

Eye drops, brimonidine tartrate 0.2% (5mL)      

Notes:

  • Brimonidine is a selective alpha2-adrenoceptor stimulant, licensed for use in those patients who are unresponsive to beta-blockers or if beta-blockers are contra-indicated.
  • There is a high incidence of ocular reactions with long-term use of brimonidine, for example sore red eyes, usually of delayed onset (several months).
11.06 Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan®

Eye drops, brimonidine tartrate 0.2%, timolol (as maleate) 0.5% 

11.06 Brinzolamide Azopt

Eye drops, brinzolamide 10mg/mL 

11.06 Brinzolamide 1% with Timolol 0.5%  Azarga®

Eye drops, brinzolamide 10mg, timolol (as maleate) 5mg/mL

11.06 Brinzolamide 10mg/ml & brimonidine 2mg/ml Simbrinza®

Eye drops, brinzolamide 10mg and brimonidine tartrate 2mg/mL equivalent to 1.3mg of brimonidine

 

04.08.01 Brivaracetam 
  • Tablets 10mg, 25mg, 50mg, 75mg, 100mg
  • Oral solution 10mg/mL 
  • Intravenous injection 10mg/mL (Hosp only)

 

Note:

  • Restricted. Only used when all other options have been tried or when prescribed by a specialist in epilepsy.
13.05.02 Brodalumab Kyntheum®

210mg/1.5ml solution for injection pre-filled syringes 

06.07.01 Bromocriptine 

Tablets 1mg, 2.5mg

Capsules 5mg, 10mg

01.05.02 Budesonide Budenofalk®

Gastro resistant capsules - Enteric coated granules 3mg

01.05.02 Budesonide Budenofalk®

Rectal foam 2mg per actuation 

Note: £57.00 for a 14-dose container with 14 applicators

01.05.02 Budesonide Entocort®

Entocort CR - Modified release capsules - 3mg

03.02 Budesonide Budelin Novolizer®

Novoliser (DPI) 200 micrograms

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar.

03.02 Budesonide Pulmicort®

Pulmicort Turbohaler® (DPI) 100, 200 & 400 microgram per inhalation

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar.

03.02 Budesonide / Formoterol Symbicort®

Symbicort (Budesonide / Formoterol)

  • Turbohaler® dry powder inhaler  100/6; 200/6; 400/12
  • MDI® 200/6

Some adult asthma patients may benefit from using Symbicort® as Maintenance And Reliever Therapy (SMART)

Allowing patients to increase dose when their asthma worsens, avoiding the need for multiple inhalers.

Only suitable for patients over 18 years where treatment with a combination of inhaled corticosteroid and LABA agonist is appropriate.

Symbicort 400/12 is not licensed for use in this way.

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar.

03.02 Budesonide and Formoterol Fobumix

Breath-actuated dry powder inhaler (DPI):

  • Fobumix Easyhaler 80/4.5 - licensed for MART therapy
  • Fobumix Easyhaler 160/4.5 - licensed for MART therapy
  • Fobumix Easyhaler 320/9

 MART = Maintenance And Reliever Therapy

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar.

03.02 Budesonide Easyhaler® 

Budesonide Easyhaler® (DPI) 100, 200, 400 microgram per inhalation

Under 6 years, not recommended

 

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar.

03.02 Budesonide nebuliser liquid unit dose vials 

Respiratory solution 500 micrograms/2ml, 1mg/2ml

02.02.02 Bumetanide 
  • Tablets 1mg, 5mg
  • Oral liquid 1mg/5mL
  • Injection 500 micrograms/mL (2mg/4mL)
04.07.02 Buprenorphine Temgesic®

Sublingual tablet 200 micrograms

04.07.02 Buprenorphine Patch
  • Patches (BuTrans®) (Amber 2) releasing 5 micrograms/hour for 7 days, 10 micrograms/hour for 7 days, 20 micrograms/hour for 7 days
  • Patches (Transtec®) (Amber 2) releasing 35 micrograms/hour for 96 hours, 52.5 micrograms/hour for 96 hours, 70 micrograms/hour for 96 hours

 

Notes:

  • Buprenorphine patches are not suitable, or licensed, for use in the management of acute or intermittent pain.
  • Prescribers should ensure that patients and/or their careers are aware that Butrans® patches need to be applied at appropriate seven-day intervals to ensure that patients are not left in pain (because of too long an interval) and that the patches are not used wastefully (because of too short an interval).
  • Remember to remove the old patch before application of new patch.
  • To increase the dose, a higher strength patch should replace the patch that is currently being worn, rather than multiple patches being used.
04.10.02 Bupropion Hydrochloride Zyban®

Modified Release Tablets 150mg

CSM advice:

  • Bupropion is contra-indicated in patients with a history of seizures or of eating disorders, a CNS tumour, or who are experiencing acute symptoms of alcohol or benzodiazepine withdrawal.
  • Bupropion should not be prescribed to patients with other risk factors for seizures unless the potential benefit of smoking cessation clearly outweighs the risk.
  • Factors that increase the risk of seizures include concomitant administration of drugs that can lower the seizure threshold (e.g. antidepressants, antimalarials (such as mefloquine and chloroquine), antipsychotics, quinolones, sedating antihistamines, systemic corticosteroids, theophylline, tramadol), alcohol abuse, history of head trauma, diabetes, and use of stimulants and anorectics.
  • Initiated under primary care specialist supervision as part of a programme of behavioural support.
06.06.02 Burosumab  Crysvita®
  • Injectable solution in single-dose vials 10mg/mL, 20mg/mL, 30mg/mL
04.01.02 Buspirone Hydrochloride 

 Tablets 5mg, 10mg  

08.01.01 Busulfan 

Myleran® Tablets 2mg

08.01.05 Cabazitaxel Jevtana®

Jevtana® 40mg/mL, (60mg/1.5-mL) Concentrate and solvent for solution for
infusion vials

Notes:
Incompatible with PVC.

Solvent contains ethanol

 

04.09.01 Cabergoline 

 Tablets 1mg, 2mg

 

Notes:

Cabergoline: Please remember to optimize patient's prescription as their doses change; two 1mg tablets are considerably more costly than one 2mg tablet.

06.07.01 Cabergoline 

Tablets 1mg, 2mg

08.01.05 Cabozantinib Cometriq®

Cometriq® Capsules 20mg, 80mg
Cabometyx® 20mg, 40mg, 60mg tablets

Notes:

NHSE Position Statement.

03.01.02 Caffeine Citrate 
  • Oral solution 10mg/ml
  • Solution for injection 10mg/ml
  • Solution for infusion 20mg/ml (Peyona)
17 CAFFEINE CITRATE 20mg/ml INJ  

Solution for infusion 20mg/mL (Peyona®)

Note:

  • Off label use for low pressure headaches
  • For Hospital Consultant Neurologist recommendation and / or initiation only.
  • Typical IV dose - Caffeine 500mg in 500ml normal saline over 2 hours stat
13.03 Calamine 
  • Calamine  Lotion 

Notes: 

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase

 

13.05.02 Calcipotriol Dovonex®
  • Scalp solution, 50 micrograms/mL
  • Ointment, 50 micrograms/g
13.05.02 Calcipotriol 50micrograms/g with Betamethasone 0.05% 
  • Dovobet® Ointment, calcipotriol 50 microgram/g + betamethasone 500 microgram/g
  • Dovobet® Gel, calcipotriol 50 microgram/g + betamethasone 500 microgram/g
  • Enstilar® Foam, calcipotriol 50 microgram/g + betamethasone 500 microgram/g (Amber 2)
06.06.01 Calcitonin (salmon) / Salcatonin 

Injection 400 units in 2ml

Short courses of calcitonin (eg. three times a week for up to 3 months) may be considered for those patients with fragility fractures if alternative analgesics have been unsuccessful.

In Haemato Oncology it is used to correct hypercalcaemia linked to the
following :
Highest in patients with multiple myeloma and breast cancer
Intermediate in patients with non-small cell lung cancer and lymphoma
Rare in patients with renal cell, colon, and small cell lung cancer
When: For hypercalcemia greater than or equal to 4 mmol/L
Dose: IM/SC Calcitonin: 4-8 unit/kg every 6h x 2 days

09.06.04 Calcitriol 
  • Capsules 250 nanograms, 500 nanograms
  • Injection 1 microgram in 1mL, 2 micrograms in 1mL 
13.05.02 Calcitriol Ointment 3 micrograms/g Silkis®

3 microgram/g

Note:  Licensed for use on the face and in the flexures.

09.05.01.01 Calcium Chloride 

Min-I-jet 10mL 

 

Shortage of supply (23/03/2020) - Calcium chloride 10% pre-filled syringes:

Calcium chloride pre-filled syringes 10% (6.8 mmol in 10 ml) are licensed for use in cardio-pulmonary resuscitation, as well as the treatment of hypocalcaemia and calcium deficiency states. 

The 10 ml pre-filled syringe of calcium chloride 10% is the preparation listed in the Resus Council list of drugs for intravenous use for cardiac- and peri-arrest. In cardiac arrest caused by hyperkalaemia, hypocalcaemia, or overdose of calcium channel-blocking drugs, an initial dose of 10 ml of 10% calcium chloride (6.8 mmol Ca2+) is recommended, which may be repeated if necessary.

Calcium chloride 10% pre filled syringes are out of stock, we do not currently have a clear date for resolution.

Alternative agents and management options

Calcium gluconate injection is an alternative to calcium chloride. In order to manage this shortage, some of the cardiac arrest boxes will contain calcium gluconate ampoules instead of calcium chloride pre-filled syringes.

It is important to note that there is a difference in calcium content:

10 ml of 10% calcium chloride pre-filled syringes contains 6.8 mmol calcium whereas 10 ml of 10% calcium gluconate contains 2.26 mmol calcium.

The Resus Council mentions use of calcium gluconate as an alternative, highlighting difference in calcium content, you would need to administer 30mls of calcium gluconate to achieve 6.78 mmol calcium and during CPR, if required, it should be given as a rapid bolus injection followed by a 0.9% sodium chloride flush.

Administration

Calcium gluconate can be given as a slow IV injection in an emergency (e.g. severe acute hypocalcaemia, cardiac resuscitation, hypocalcaemic tetany). Give each 10mL of undiluted injection over at least 5 minutes, while monitoring plasma-calcium and ECG. (Resus Council advises can be given as rapid bolus injection during CPR).

Safety:

Calcium gluconate undiluted has a high osmolarity and may cause venous irritation and tissue damage in cases of extravasation.

There may be certain patients, for example in critical care and those with severe liver impairment, for whom the increased volume of gluconate or the time taken to infuse this additional volume may be problematic, and any remaining stock of chloride may need to be prioritised for this group.

 

 

09.05.01.01 Calcium Gluconate 

10mL ampoule 

06.01.02.03 Canagliflozin Invokana®

Invokana® Tablets 100mg, 300mg

06.01.02.03 Canagliflozin / metformin IR Vokanamet®

Vokanamet® Tablets f/c 50mg/850mg, 50mg/1g

 

08.02.04 Canakinumab Ilaris®

Ilaris injection, powder for reconstitution, 150mg vial

02.05.05.02 Candesartan 

Tablets 2mg, 4mg, 8mg, 16mg, 32mg

04.07.04.02 Candesartan 

(Off-label indication)

Tablets 2mg, 4mg, 8mg, 16mg

20 Cannabidiol (CBD) 

Note:  Specialist use only, strictly in line with NICE Guidance.

Use as per NICE TAs (see links below).

10.02.02 Cannabis extract Sativex®

Cannabidiol 2.5mg per 1 dose, dronabinol 2.7mg per 1 dose

Note:  Specialist use only, strictly in line with NICE Guidance.

08.01.03 Capecitabine Xeloda®

Tablets 150mg, 500mg

 

10.03.02 Capsaicin Qutenza®

Patch 179mg

For use only in the Pain Clinic.

04.07.03 Capsaicin cream 

Axsain® Cream 0.075% (Capsaicin 750 microgram per 1 gram) 

Notes:

  • For the management of local neuropathic pain in patients who cannot tolerate oral medication.
  • Apply sparingly 3–4 times daily (no more than every 4 hours).
  • Review after 8 weeks.
04.07.03 Capsaicin patch 

Qutenza® 179mg Cutaneous patch

02.05.05.01 Captopril 
  • Tablets 12.5mg, 25mg, 50mg 
  • Noyada® oral solution sugar free 5mg/5mL, 25mg/5mL (Paediatric use only)
04.02.03 Carbamazepine 
  • Tablet 100mg, 200mg, 400mg
  • Modified Release tablet 200mg, 400mg
  • Chewable tablet 100mg
  • Oral suspension Sugar Free 100mg in 5mL
  • Suppository 125mg, 250mg   
04.08.01 Carbamazepine 
  • Tablet 100mg, 200mg, 400mg
  • Modified Release tablet 200mg, 400mg
  • Chewable tablet 100mg
  • Oral suspension Sugar Free 100mg in 5mL
  • Suppository 125mg, 250mg 
06.02.02 Carbimazole 

Tablets 5mg, 20mg

notes:

 

CSM warning: Neutropenia and agranulocytosis.
Doctors are reminded of the importance of recognising bone marrow
suppression induced by carbimazole and the need to stop treatment promptly.
Patients should be asked to report symptoms and signs suggestive of infection, especially sore throat or mouth ulcers.


A white blood cell count should be performed if there is any clinical evidence of infection.


Carbimazole should be stopped promptly if there is clinical or laboratory evidence of neutropenia.

03.07 Carbocisteine 
  • Capsules 375mg
  • Oral liquid 250mg/5mL
  • Oral solution SF 750mg in 10ml; 15x10ml sachets

Note:

Mucolytic therapy - Consider in people with a chronic productive cough and only continue use if symptoms improve. Do not routinely use to prevent exacerbations.

11.08.01 Carbomer eye drops 

 Clinitas Carbomer gel 0.2%

Note:

  • Suitable for contact lens wearers
08.01.05 Carboplatin 

Injection 50mg in 5mL, 450mg in 45mL, 600mg in 60mL

 

07.01.01 Carboprost Hemabate®

Injection 250 micrograms /1ml

 

Carboprost is only indicated for postpartum haemorrhage due to uterine atony
in patients unresponsive to ergometrine and oxytocin.

Misoprostol (unlicensed) can be used in postpartum haemorrhage when oxytocin, ergometrine, and carboprost are not available or are in apporpriate.

Tranexamic acid is used to decrease blood loss in surgery and health conditions associated with increased bleeding. there have been some reviews that have found that tranexamic acid is also effective in reducing blood loss post partum.

12.03.01 Carmellose Sodium Orabase®

Orabase® protective paste

Notes:

  • Orabase® is cheap and effective in providing mechanical protection of oral and perioral lesions.
11.08.01 Carmellose Sodium 0.5% 
  • Optive eye drops (Carmellose sodium 0.5%, glycerol 0.9%)
  • Optive Fusion eye drops (sodium hyaluronate 0.1%, carmellose sodium 0.5%, glycerol 0.9%)

Notes:

  • Contains preserving system which biodegrades on contact with the eye.
  • 6 month expiry once open.
  • Suitable for contact lens wearers.
11.08.01 Carmellose sodium 0.5% (Optive Plus®) eye drops 

Optive Plus eye drops (Carmellose sodium 0.5%, glycerol 1%, castor oil 0.25%)

Notes:

  • For use in evaporative dry eyes (for hospital specialist initiation)
11.08.01 Carmellose Sodium 1% Celluvisc

Celluvisc eye drops (Carmellose sodium 1% Preservative-Free single use eye drops)

Notes:

  • Suitable for contact lens wearers.
08.01.01 Carmustine BiCNU®

BiCNU® injection, powder for reconstitution 100mg vial U

 

02.04 Carvedilol 

Tablets 3.125mg, 6.25mg, 12.5mg, 25mg

05.02.04 Caspofungin 

Cancidas® Intravenous Infusion, powder for reconstitution, 50mg, 70mg vials

07.04.04 Catheter Patency Solutions 

1 litre, 3 litre, Uro-tainer, Pour bottle

07.04.04 Catheter Patency Solutions 

Suby G uro-tainer

05.01.02.01 Cefalexin 

Capsules 250mg, 500mg

Oral suspension 125mg/5ml, 250mg/5ml

05.01.02.01 Cefixime Suprax®

Tablets 200mg

Note:

Cefixime has been included for the treatment of urogenital gonorrhoea only and is not considered reliable for the treatment of pharyngeal disease.

05.01.02.01 Cefotaxime 

Injection 500mg, 1gram, 2 grams,

05.01.02.01 Ceftazidime 

Injection 500mg, 1gram, 2gram, 3gram

05.01.02.01 Ceftriaxone 

Injection 250mg, 1gram, 2gram

05.01.02.01 Cefuroxime 

Injection 250mg, 750mg, 1.5 grams

11.03.01 Cefuroxime  Aprokam®

Aprokam® - Specialist use only

  • Intracameral Injection 50mg powder for solution for injection in vial plus filter needle
05.01.02 Cefuroxime Axetil 

Injection 250mg, 750mg, 1.5g

Restricted to Maternity and Paediatric wards.

10.01.01 Celecoxib 

Tablets 100mg, 200mg

08.02.04 Cemiplimab Libtayo®

Vial

08.01.05 Ceritinib Zykadia

Zykadia® Capsule 150mg

 

10.01.03 Certolizumab Pegol Cimzia®

Cimzia® Solution for injection, 200mg in pre-filled pen or in pre-filled syringe

03.04.01 Cetirizine 

Cetirizine hydrochloride

  • Tablets 10mg
  • Oral solution 5mg/5mL

Notes:

  • Sugar-free versions are available and can be ordered by specifying sugar-free on the prescription.

Should not be prescribed in Primary Care or at Discharge.  Advise patient to purchase, unless prescription is for long-term regular use.

13.02.01 Cetraben® 

Ointment

08.01.05 Cetuximab Erbitux®

Erbitux® Intravenous Infusion, 5mg/mL in vial

 

04.01.01 Chloral Hydrate 

 Liquid 500mg in 5mL  U

Notes:

  • Choral hydrate and its derivatives are considered less suitable for prescribing. There is no convincing evidence that they are particularly useful in the elderly and their role as hypnotics is now very limited.   
08.01.01 Chlorambucil 

Tablets 2mg

05.01.07 Chloramphenicol 
  • Capsules 250mg
  • Intravenous Infusion, powder for reconstitution, 1g
11.03.01 Chloramphenicol 
  • Eye drops 0.5% 
  • Eye ointment 1%
  • Single use eye drop 0.5%

 

Notes:

  • Chloramphenicol is the drug of choice for superficial eye infections. It has a broad spectrum of activity and is associated with a low level of resistance.
  • Should not be routinely prescribed in Primary Care. Advise patient to purchase
    • Available to purchase over the counter for patients over 2 years of age
  • Most bacterial infections are self-limiting. Mild cases should not need treating.
  • May be prescribed if appropriate to in-patients. 
04.01.02 Chlordiazepoxide 

Capsules 5mg, 10mg 

13.11.02 Chlorhexidine Unisept®
  • Sachets, Chlorhexidine gluconate (25ML) 0.05 % Sachets 25 x 25mL
  • Cream, Chlorhexidine Obstetric 1 % Cream 250 mL

Notes:

  • Avoid contact with eyes, brain, meninges and middle ear
  • Not for use in body cavities
  • Alcoholic solutions not suitable before diathermy or for use on neonatal skin
  • In preterm neonates, use sparingly, do not allow solution to pool, and monitor for skin reactions—risk of severe chemical burns
13.11.02 Chlorhexidine 0.015% with Cetrimide 0.15% Tisept®
  • Savlon® antiseptic cream
  • Liquid,cetrimide 1.5mg per 1ml, chlorhexidine gluconate 150microgram per 1ml; 25ml sachets
  • Irrigation solution, 1 litre bottle

Notes for Savlon antiseptic cream: 

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term regular use

 

12.02.03 Chlorhexidine 0.1% & Neomycin 0.5% nasal cream Naseptin®

Nasal cream: chlorhexidine hydrochloride 0.1%, neomycin sulphate 0.5%  

Notes:

  • Caution - contains arachis oil 
12.03.02 Chlorhexidine gluconate mouthwash 

Mouthwash 0.2%       

Notes: 

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term regular use
  • Chlorhexidine may be used as an antiseptic to prevent secondary infection in mouth ulcers or following oral surgery. It can also prevent the formation of plaque.
12.03.04 Chlorhexidine mouthwash 
  • Mouthwash 0.2%       

Notes: 

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term regular use
  • Chlorhexidine may be used as an antiseptic to prevent secondary infection in mouth ulcers or following oral surgery. It can also prevent the formation of plaque.
10.01.03 Chloroquine 

Tablets 250mg

Syrup 68mg in 5ml (Hospital only)

05.04.01 Chloroquine Sulfate 
  • Tablets 250mg (equivalent to 155mg chloroquine base)
  • Syrup 68mg/5mL (equivalent to 50mg/ chloroquine base/5mL), Unlicensed
02.02.01 Chlorothiazide 

Suspension 250mg/5mL

Notes:

  • For Paediatric use only.
  • Tertiary Care Specialist Service / Hospital initiation with Secondary Care continuation.
03.04.01 Chlorphenamine 

Chlorphenamine maleate

  • Tablets 4mg
  • Oral solution sugar-free 2mg in 5mL
  • Injection 10mg/mL

Notes:
Patients aged over 6 should not be prescribed in Primary Care or at Discharge.  Advise patient to purchase, unless prescription is for long-term regular use.

04.02.01 Chlorpromazine 
  • Tablets 25mg, 50mg, 100mg
  • Oral solution 25mg/5mL, 100mg/5mL
  • Injection 25mg/mL (2-mL amp) 
04.06 Chlorpromazine 
  • Tablets 25mg, 50mg, 100mg
  • Oral solution 25mg/5mL, 100mg/5mL
  • Injection 25mg/mL (2-mL amp)
02.02.01 Chlortalidone 

Tablets 50mg

14.04 Cholera vaccine Dukoral®

Oral suspension

12.03.01 Choline Salicylate Bonjela® Adult

Bonjela Dental gel 8.714%   

Notes: 

  • For use in adults and children over 16 years only   
  • Should NOT be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term regular use
06.05.01 Chorionic Gonadotrophin (HCG) Pregnyl®

Pregnyl Injection with solvent 1500 units, 5000 units

01.05.03 Ciclosporin 

(Amber SCG in development)

Capsules 10mg, 25mg, 50mg, 100mg

Oral solution 100mg/mL 

08.02.02 Ciclosporin 

Neoral caosules 10mg, 25mg, 50mg, 100mg

Sandimmun concentrate for iv infusion 250mg/5ml (Hospital only)

 

Notes:
Patients should be stabilised on a particular brand of oral ciclosporin because
switching between formulations without close monitoring may lead to clinically
important changes in blood-ciclosporin concentration.


Prescribing and dispensing of ciclosporin should be by brand name to
avoid inadvertent switching.


If it is necessary to switch a patient to a different brand of ciclosporin, the
patient should be monitored closely for changes in blood-ciclosporin
concentration, serum creatinine, blood pressure, and transplant function.

10.01.03 Ciclosporin 
  • Capsules 10mg, 25mg, 50mg, 100mg
  • Oral solution 100mg/1ml

Notes:

  • Ciclosporin (Neoral) is licensed for severe active RA when conventional second-line therapy is inappropriate or ineffective.
  • It is contraindicated in abnormal renal function, uncontrolled hypertension, uncontrolled infections and malignancy.
  • Monitor hepatic function if concomitant NSAIDs given.
  • As there are differences in bioavailability, the brand of ciclosporin to be dispensed should be specified by the prescriber.
11.99.99.99 Ciclosporin 

Ikervis® 1mg/mL eye drops, emulsion

 

13.05.03 Ciclosporin 
  • capsules 10mg, 25mg, 50mg, 100m
  • Oral solution 100mg/mL 

Note:

  • Prescribe ciclosporin generically for dermatology conditions
09.05.01.02 Cinacalcet Mimpara®

Tablets 30mg, 60mg, 90mg

Notes:  GP can continue to prescribe for patients already stabilised on it.

04.06 Cinnarizine 

 Tablets 15mg  

05.01.12 Ciprofloxacin 
  • Tablet 250mg,500mg
  • Oral suspension 250mg/5mL
  • Intravenous infusion 100mg/50ml, 200mg/100ml

Note:

11.03.01 Ciprofloxacin 
  • Ophthalmic solution 0.3%
  • Eye ointment 0.3% 

Notes:

  • Ciprofloxacin eye drops should be reserved for treatment of corneal ulcers.
15.01.05 Cisatracurium Nimbex®

150mg in 30mL vial

08.01.05 Cisplatin 

Injection 10mg in 10mL, 50mg in 50mL, 100mg in 100mL

04.03.03 Citalopram 
  • Tablets 10mg, 20mg, 40mg
  • Oral drops Sugar Free 40mg in 1mL

Note:

  • Dose equivalence: 4 oral drops (8mg) is equivalent in therapeutic effect to 10mg tablet

 

 

Advice for healthcare professionals:

Maximum daily dose schedule is as follows:

  Adults Adults >65 years Adults with hepatic impairment
Citalopram 40 mg* 20 mg* 20 mg*
Escitalopram 20 mg 10 mg* 10 mg

*New (restricted) maximum daily dose.

Contraindications in patients at greatest risk of QT interval prolongation:

Citalopram and escitalopram should not be used:

    • in patients with congenital long QT syndrome or known pre-existing QT interval prolongation
    • in combination with other medicines known to prolong the QT interval
08.01.03 Cladribine Mavenclad®

Tablet 10mg

05.01.05 Clarithromycin 

Intravenous infusion 500mg

05.01.05 Clarithromycin 
  • Tablets 250mg, 500mg
  • Oral suspension 125mg/5mL, 250mg/5mL
05.01.06 Clindamycin 

Capsules 75mg, 150mg

Injection 300mg/2ml, 600mg/4ml

Clindamycin’s principal indication is second line for Gram-positive soft tissue, bone and joint infections.

It is associated with Clostridium difficile diarrhoea, which limits its use.

Patients should discontinue treatment if diarrhoea develops.

07.02.02 Clindamycin Dalacin®

2% cream

13.06.01 Clindamycin/ tretinoin gel Treclin®
19.01 Clinipore 

Adhesive Tape 2.5cm x 10cm

04.08.01 Clobazam 

Tablets 10mg

Note:

  • NHS Restriction - Clobazam is not prescribable under the NHS except for epilepsy and endorsed 'SLS'
13.04 Clobetasol propionate Clarelux®
  • Ointment, clobetasol propionate 0.05%
  • Cream, clobetasol propionate 0.05%
13.04 Clobetasol Propionate 0.05% Dermovate®
  •  Ointment, 0.05% 
  •  Cream, 0.05% 
13.04 Clobetasol Propionate with neomycin and nystatin Dermovate-NN®
  • Ointment
  • Cream
13.04 Clobetasone Butyrate 0.05% Eumovate®

Cream

Notes:

  • Clobetasone butyrate (Eumovate®) cream can be sold over the counter for short-term symptomatic treatment and control of patches of eczema and dermatitis (but not seborrhoeic dermatitis) in adults and children over 12 years.
13.04 clobetasone butyrate 0.05%, oxytetracycline 3%, nystatin 100,000 units/g Trimovate®

Cream, clobetasone butyrate 0.05%, oxytetracycline 3%, nystatin 100,000 units/g

Notes:

stains clothing

06.06.02 Clodronate Sodium 

Tablets 520mg, 800mg

04.01.01 Clomethiazole Heminevrin®

 Capsule 192mg

06.05.01 Clomifene Citrate Clomid

Tablets 50mg

Specilaist prescribing only.

CSM advice: Clomifene should not normally be used for longer than 6 cycles (possible increased risk of ovarian cancer)

04.03.01 Clomipramine 

Capsules 10mg, 25mg, 50mg

04.02.03 Clonazepam 
  • Tablet 500microgram, 2mg   
  • Intravenous injection 1mg/mL or infusion of 1mg
04.08.01 Clonazepam 
  • Tablet 500microgram, 2mg   
  • Intravenous injection 1mg/mL or infusion of 1mg
02.05.02 Clonidine 
  • Tablets 100 micrograms and 25 micrograms
  • Injection 150 micrograms/1mL

Notes: Other uses of clonidine

  • Licensed: Prevention of recurrent migraine; prevention of vascular headache
  • Unlicensed: Tourette syndrome and sedation 
02.09 Clopidogrel 
  • Tablets 75mg
  • Tablets 300mg (Hospital only)

Notes:

  • Concomitant use of clopidogrel and omeprazole or esomeprazole is to be discouraged.
  • Dual anti-platelet therapy (aspirin plus clopidogrel) for longer than 12 months is unlicensed.
07.02.02 Clotrimazole 

Cream 1%

Intravaginal cream 10%

Pessary 500mg

12.01.01 Clotrimazole 

Solution 1%

13.10.02 Clotrimazole 
  • Cream 1% 
  • Solution 1%   
04.02.01 Clozapine Denzapine® or Clozaril®

Tablets 25mg, 100mg

Notes:

  • For treatment-resistant schizophrenia. Initiated by consultant psychiatrist only.
  • Prescribe by brand (CNWL-MK preferred brand - Clozaril®).
  • All patients, prescribers and dispensing pharmacists must be registered with Clozaril® Patient Monitoring Service (CPMS).
  • Clozaril Patient Monitoring Service - https://www.clozaril.co.uk/scrLogon.asp (Password required)
13.09 Coal Tar Polytar®

Shampoo

Notes: 

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term regular use
13.05.02 Coal tar lotion 5% Exorex®

Exorex® Lotion

Polytar® Shampoo

Notes: 

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term regular use
13.09 Coal tar with coconut oil and salicylic acid Capasal®

 Shampoo 

  • Capasal® Shampoo 

Notes: 

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term regular use
02.02.04 Co-amilofruse 

Tablets 2.5mg/20mg, 5mg/40mg  (amiloride/furosemide)

Note: Although it is generally considered preferable to prescribe diuretics separately, the use of fixed combinations may be justified if compliance is a problem.

02.02.04 Co-amilozide 

Tablets 2.5mg/25mg, 5mg/50mg

05.01.01.03 Co-Amoxiclav 

Tablets 250mg/125mg, 500mg/125mg

Oral suspension 125mg/31mg in 5ml, 250mg/62mg in 5ml

Injection 500mg/100mg, 1000mg/200mg (Hospital only)

04.09.01 Co-Beneldopa Madopar®
  • Capsule 62.5mg, 125mg, 250mg
  • Dispersible tablets 62.5mg, 125mg
  • Modified Release capsule 125mg
04.09.01 Co-Careldopa Sinemet®
  • Tablets 62.5mg, 110mg, 125mg, 275mg
  • Modified Release tablets 125mg, 250mg

 

Notes:

  • Patient and Carer advice: Sudden onset of sleep - Excessive daytime sleepiness and sudden onset of sleep can occur with co-careldopa, co-beneldopa, and the dopamine receptor agonists. Patients starting on treatment with these drugs should be warned of the possibility of these effects and of the need to exercise caution when driving or operating machinery. Patients, who have suffered excessive sedation or sudden onset of sleep, should refrain from driving or operating machines, until those effects have stopped.
  • When co-careldopa (10/100) is used, the dose of carbidopa may be insufficient to achieve full inhibition of extracerebral dopa-decarboxylase; co-careldopa 25/100 should therefore be used so that the daily dose of carbidopa is at least 75mg.
  • Levodopa therapy should be initiated with low doses and gradually increased, by small increments, at intervals of 2-3 days. The final dose is usually a compromise between increased mobility and dose-limiting side effects.
  • Modified release preparations may help with “end-of-dose” deterioration or nocturnal immobility and rigidity.
04.09.01 Co-Careldopa and Entacapone Stalevo®
  • Tablets levodopa 50 mg, carbidopa 12.5 mg, entacapone 200 mg
  • Tablets levodopa 75 mg, carbidopa 18.75 mg, entacapone 200 mg
  • Tablets levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg
  • Tablets levodopa 125 mg, carbidopa 31.25 mg, entacapone 200 mg
  • Tablets levodopa 150 mg, carbidopa 37.5 mg, entacapone 200 mg
  • Tablets levodopa 175 mg, carbidopa 43.75 mg, entacapone 200 mg
  • Tablets levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg  
13.06.02 Co-Cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 Dianette®

Notes:

  • See current BNF for cautions and further information before initiating co-cyprindiol  

 

01.06.02 Co-danthramer 
  • Capsules (standard strength) 25/200mg
  • Strong capsules 37.5/500mg
  • Oral suspension 25/200mg in 5mL
01.06.02 Co-danthrusate 

Capsules 50/60 (dantron 50mg, docusate sodium 60mg)

Notes:

  • The CSM (May 2000) have advised that the indication for danthron containing products has been restricted to constipation in terminally ill patients of all ages. Therefore, co-danthramer and co-danthrusate are included as Specialist Initiated Drugs.
  • Most terminally ill patients require both a softening agent and a stimulant laxative, for example.
03.09.01 Codeine Linctus BP 

For use in Palliative Care only.

04.07.02 Codeine Phosphate 
  • Tablet 15mg, 30mg
  • Oral solution 25mg in 5mL
  • Injection 60mg in 1mL - CD (Hospital only)

 

Note:

  • Codeine is effective for the relief of mild to moderate pain but is too constipating for long-term use.
  • Codeine is contraindicated in all patients of any age known to be CYP2D6 ultra-rapid metabolisers.
02.14 Colchicine 
  • For acute and recurrent pericarditis
  • 500 microgram tablets

Notes:

  • Colchicine does not currently have a licence to be used to treat pericarditis in the UK. However, studies have shown that colchicine can be effective in treating pericarditis.
  • Colchicine is recommended on top of standard anti-inflammatory therapy, without a loading dose and using weight adjusted doses (500 micrograms daily if body weight is less than 70kg, or 500 micrograms twice daily if body weight is equal or greater than 70kg, for at least 6 months).
10.01.04 Colchicine 

Tablets 500 micrograms

Notes:

  • High doses of NSAIDs or colchicine may be used for the treatment of acute attacks of gout. Caution: NSAID toxicity in high risk (especially older) patients and GI toxicity with colchicine.
  • Colchicine is of value for patients with heart failure since, unlike NSAIDs, it does not induce fluid retention.
  • It can also be given to patients receiving anticoagulants.
  • 500 micrograms every 2-4 times daily until relief of pain is obtained or vomiting or diarrhoea occurs or until a total dose of 6mg (12 tablets) has been reached.
  • The course should not be repeated within 3 days.
  • Colchicine has a narrow therapeutic window and is extremely toxic in overdose. Patients at particular risk of toxicity are those with renal impairment, gastrointestinal or cardiac disease, and patients at extremes of age. The symptoms of overdose are often delayed.
09.06.04 Colecalciferol 2,400 units/ml drops Invita D3® oral drops
  • 800 unit capsules containing colecalciferol 
  • 5,600 unit capsules containing colecalciferol (This strength allows weekly dosing)
  • 50,000 unit capsules containing colecalciferol 
  • 25,000 units/mL oral solution 
  • 50,000 units/mL oral solution 
  • 2,400 units/mL oral drops, solution

Note:  May be mixed with a small amount of cold or lukewarm food immediately before administration.

09.06.04 Colecalciferol 20,000 unit capsules Fultium D3®

Capsules containing 20,000 unit (= 500 micrograms Vitamin D)

09.06.04 Colecalciferol 3,000 units per ml liquid 

Liquid 3,000 units in 1mL

09.06.04 Colecalciferol 4000 units Desunin®

Tablet 800 unit

02.12 Colesevelam 

Cholestagel® 625mg Tablets

Notes:

  • For patients with proven Bile Acid Malabsorption (BAM) and have either failed or are intolerant of colestyramine. 
  • Off-label use.
  • The patient will be reviewed within 1 month to assess efficacy and the medication stopped if there is no improvement in symptoms or it is not tolerated.
02.12 Colestipol Colestid®

Colestid® granules for oral suspension 5g

02.12 Colestyramine 

Powder, sugar free 4g sachet 

05.01.07 Colistimethate 
  • Colomycin® Injection 1million-unit vial - Powder for solution for injection, infusion or inhalation
  • Colomycin® Injection 2million-unit vial - Powder for solution for injection, infusion or inhalation
  • Promixin® 1million-units - Powder for Nebuliser Solution
  • Promixin® 1million-units - Powder for Solution for Infusion (available via Homecare only)
  • Colobreathe® - Dry powder for inhalation, hard capsule, 1.66 million units/capsule (with Turbospin® inhaler device)
10.03.01 Collagenase Xiapex®

Xiapex 0.9mg powder and solvent for solution for injection in vial

Note:

  • Treatment of Dupuytren's contracture is a "procedure of limited clinical value".
    Follow criteria on MKCCG website
    - http://www.miltonkeynesccg.nhs.uk/referrals-and-priorities-policies/

 

01.01.01 Co-magaldrox Mucogel®
  • Hospital preference: Mucogel® Suspension SF 500mL ('Low Sodium' - sodium content less than 1mmol per 10mL dose)
  • Primary Care to specify most cost-effective brand 
A2.02.01 Complan® Shake 

Complan® powder milkshake and Complan® Chicken powder soup are available to buy over the counter or online and are an option if patient does not meet ACBS Criteria.

06.04.01.01 Conjugated oestrogens Premarin®

Conjugated oestrogens 300 microgram, 625 microgram , 1.25mg tablets as Premarin®

Unopposed oestrogen (if uterus is intact an adjunctive progestogen must be used), hysterectomy

Prescription charge - 1

05.01.08 Co-trimoxazole 
  • Tablets 480mg, 960mg
  • Suspension 240mg/5ml, 480mg/5ml
  • Injection 480mg / 5ml (Hopsital only)

Note:

CSM recommends that co-trimoxazole should be limited to treatment and prevention of pneumocystis pneumonia.

08.01.05 Crisantaspase Erwinase®

Injection, powder for reconstitution 10000 unit vial

08.01.05 Crizotinib Xalkori®

Xalkori® Capsules 200mg, 250mg

 

13.03 Crotamiton Eurax®
  • Eurax® 10% cream (contains beeswax, fragrance, hydroxybenzoates (parabens), stearyl alcohol) 

Notes: 

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term regular use
  • Crotamiton dries skin, and is therefore not suitable for use in eczema.
19 Cutimed® Sorbact 

4cm x 6cm

7cm x 9cm

Cutimed web site with indications

09.01.02 Cyanocobalamin 

Tablets 50 micrograms

Notes:

Tablets for dietary deficiency are selfcare.

Hydroxocobalamin has completely replaced cyanocobalamin as the form of vitamin B12 of choice for therapy; it is retained in the body longer than cyanocobalamin and thus for maintenance therapy can be given at intervals of up to 3 months.

Neo-Cytamen® injection is blacklisted and prescriptions must be written for generic hydroxocobalamin to be allowable on FP10 prescription.

Folinic acid tablets (calcium folinate), used to counteract the folate-antagonistic action of methotrexate.

04.06 Cyclizine 
  • Tablets 50mg
  • Injection 50mg in 1mL 
11.05 Cyclopentolate  
  • Eye drops 0.5%, 1% 
  • Minims® Single use unit dose eye drops 0.5%, 1% 

     

08.01.01 Cyclophosphamide 

Injection 500mg vial, 1g vial (Hospital only)

Tablets 50mg

08.03.04.02 Cyproterone 

Tablets 50mg, 100mg

Note:
Hepatotoxicity: Direct hepatic toxicity including jaundice, hepatitis and
hepatic failure has been reported (usually after several months) in patients
treated with cyproterone acetate 200-300 mg daily. Liver function tests should
be performed before treatment and whenever symptoms suggestive of
hepatotoxicity occur-if confirmed cyproterone should normally be withdrawn.

Cyproterone is no longer recommended for long term use.

06.04.02 Cyproterone Acetate 

Tablets 50mg, 100mg

NOTE

Hepatotoxicity : Direct hepatic toxicity including jaundice, hepatitis and hepatic failure has been reported (usually after several months) in patients treated with cyproterone acetate 200 - 300mg daily. Liver function tests shouls be performed before treatment and whenever symptoms suggestive of hepatotoxicity occur - if confirmed cyproterone should normally be withdrawn. Cyproterone is no longer recommended for long term use.

08.01.03 Cytarabine 

Injection 100mg in 5mL, 500mg in 5mL, 500mg in 25mL, 1g in 10mL, 2g in
20mL

DepoCyte® lipid formulation intrathecal injection 50mg vial

02.08.02 Dabigatran Pradaxa®

Capsules 75mg, 110mg, 150mg (Hospital only)

Note:

Approved for prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.

 

08.01.05 Dabrafenib Tafinlar®

Capsule 50mg, 75mg

 

08.01.05 Dacarbazine 

Injection, powder for reconstitution 100mg, 200mg, 500mg, 1g vial

08.02.04 Daclizumab Zinbryta®

Zinbryta® Solution for injection 150mg/1mL in pre-filled syringe / in pre-filled pen

 

08.01.05 Dacomitinib 
08.01.05 Dacomitinib monohydrate Vizimpro®

Tablets 15 mg, 30 mg, 45 mg.

08.01.02 Dactinomycin 

Injection, powder for reconstitution 500 microgram vial (Available by special
order)

02.08.01 Dalteparin sodium Fragmin®
  • Injection 2500 units in 0.2mL pre-filled syringe
  • Injection 5000 units in 0.2mL pre-filled syringe
  • Injection 7500 units in 0.3mL pre-filled syringe
  • Injection 10000 units in 0.4mL pre-filled syringe
  • Injection 12500 units in 0.5mL pre-filled syringe
  • Injection 15000 units in 0.6mL pre-filled syringe
  • Injection 18000 units in 0.72mL pre-filled syringe 
  • Injection 10000 units in 1mL pre-filled graduated syringe 

Note: Discharge supplies - Patients with GPs in MK are supplied 14 days of dalteparin on discharge and GP is expected to continue therapy.

06.07.02 Danazol 

Capsules 100mg, 200mg

10.02.01 Dantrolene 

Capsules 25mg, 100mg

15.01.08 Dantrolene Sodium Dantrium Intravenous®

 20mg vial Powder for solution for injection

 

 

06.01.02.03 Dapagliflozin Forxiga®

Forxiga® Tablets 5mg, 10mg

Note:

  • Evidence-based recommendations on dapagliflozin with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a body mass index (BMI) of at least 27 kg/m2. See NICE TA597 below for further details.
06.01.02.03 Dapagliflozin / metformin Xigduo®

Xigduo® Tablets 5mg/850mg, 5mg/1g

 

05.01.10 Dapsone 

Tablets 50mg, 100mg

Note:

For long-term treatment, patients and their carers should be told how to recognise the signs of blood disorders and advised to seek immediate medical attention if symptoms such as fever, sore throat, rash, mouth ulcers, purpura, bruising, bleeding develop.

05.01.07 Daptomycin Cubicin®

Intravenous infusion, powder for reconstitution 350mg, 500mg

08.01.05 Daratumumab Darzalex®

Darzalex® 20mg/mL concentrate for solution for infusion

 

09.01.03 Darbepoetin Alfa Aranesp®
  • Aranesp® Injection, prefilled syringes - 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300, 500 micrograms
  • Aranesp® Injection, SureClick prefilled disposable pens 20, 40, 60, 80, 100, 150, 300, 500 micrograms 
07.04.02 Darifenacin Emselex®

Tablets modified release 7.5mg, 15mg

05.03.01 Darunavir Prezista®

Tablets, 400mg, 600mg, 800mg

05.03.01 Darunavir and Cobicistat Rezolsta®

Tablets film-coated, 800mg/150mg 

08.01.05 Dasatinib Sprycel®

Sprycel® Tablets film-coated 20mg, 50mg, 80mg, 100mg, 140mg

 

08.01.02 Daunorubicin 

Injection, powder for reconstitution 20mg vial 

08.03.04.02 Degarelix Firmagon®

Firmagon® Injection, powder and solvent for solution 80mg, 120mg

Notes:
Under 18 years, not recommended

 

05.01.03 Demeclocycline 

Capsules 150mg

For the treatment of chronic hyponatraemia associated with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) secondary to malignant disease, where water restriction is ineffective and the patient does not have concomitant cirrhosis.

06.06.02 Denosumab Prolia®

Subcutaneous injection 60mg per ml as Prolia® Injection 60mg/mL (prefilled syringe)

Note:

 


Risk of fracture secondary to multiple myeloma if intolerant of or unable to have
bisphosphonates

13.02.01 Dermol® 

Emollient preparation with antimicrobials

09.01.03 Desferrioxamine Mesilate 

Injection, powder for reconstitution, 500mg vial

15.01.02 Desflurane Suprane®

240mL

06.05.02 Desmopressin 

Tablets 100 microgram, 200 microgram

Nasal spray 10 microgram per metered spray

Injection 4 microgram in 1ml

15 micrograms in 1ml. (Hospital only)

07.03.02.01 Desogestrel 

Desogestrel 75 microgram

Oral progestrogen-only contraceptive

Prescribe generically

06.03.02 Dexamethasone 

Tablets 500micrograms, 2mg

Injection (as sodium phosphate) 3.8mg in 1mL

Tablets, soluble 2mg, 4mg, 8mg

Oral solution Sugar free 2mg in 5mL

Elixir 500micrograms in 5mL (Unlicensed)

 

10.01.02.02 Dexamethasone 

Injection 8mg in 2ml

11.04.01 Dexamethasone Maxidex ®
  • Eye drops 0.1%, hypromellose 0.5%
  • Single use eye drop 0.1%
11.04.01 Dexamethasone intravitreal implant Ozurdex®

Ozurdex® Intravitreal implant containing dexamethasone 700 micrograms in disposable applicator

11.04.01 Dexamethasone with (Hypromellose), Neomycin and Polymyxin B Sulfate Maxitrol®
  • Eye drops: dexamethasone 0.1%, hypromellose 0.5%, neomycin 0.35%, polymixin B sulfate 6000 units/ml
  • Eye ointment: dexamethasone 0.1%, neomycin 0.35%, polymixin B sulfate 6000 units/ml

Notes:

  • Use of a combination product containing a steroid plus antibiotic is rarely justified and should not be routinely used, except post intraocular surgery e.g. cataract  
12.01.01 Dexamethasone with Antibacterial Otomize®

Ear Spray: dexamethasone 0.1%, neomycin sulphate 3250 units/ml, glacial acetic acid 2% 

12.01.01 Dexamethasone with Antibacterials Sofradex®

Ear drops: Dexamethasone 0.05%, framycetin sulphate 0.5%, gramicidin 0.005%     

Notes:

  • Considered to be a "Drug of Limited Clinical Value"  
04.04 Dexamfetamine 

 Tablets 5mg 

04.07.02 Diamorphine 
  • Injection 5mg, 10mg, 30mg, 100mg, 500mg
  • Ayendi® Nasal Spray 720microgram/actuation 
  • Ayendi® Nasal Spray 1600microgram/actuation
04.01.02 Diazepam 
  • Tablets 2mg, 5mg, 10mg
  • Oral solution 2mg in 5mL
  • Injection (emulsion - Diazemuls®) 5mg/mL (2-mL amp)
  • Injection (solution) 5mg/mL (2-mL amp)
  • Rectal solution tube 2.5mg, 5mg, 10mg

 

Notes:

  • Diazepam is the preferred benzodiazepine for the treatment of anxiety and in benzodiazepine withdrawal regimes.
  • Benzodiazepines are associated with a poorer outcome in the long term and should not be prescribed for the treatment of individuals with panic disorder.
04.08.02 Diazepam epilepsy
  • Tablets 2mg, 5mg, 10mg
  • Solution for injection 10mg/2ml
  • Oral suspension 2mg/5ml
  • Oral solution 2mg/5ml
  • Enema 2.5mg tubes, 5mg tubes, 10mg tubes
06.01.04 Diazoxide 

Tablets 50mg

10.01.01 Diclofenac 
  • Tablets e/c 25mg, 50mg
  • Dispersible tablets 50mg
  • Suppositories 12.5mg, 25mg, 50mg, 100mg
  • Injection 75mg in 3ml

AKIS 75 mg/ml solution for injection - Hospital Use only

01.02 Dicycloverine hydrochloride 

Oral solution 10mg/5mL 

05.03.01 Didanosine Videx®
  • Videx® Tablets chewable/dispersible, 25mg
  • Videx® Capsules gastroresistant 125mg, 200mg, 250mg, 400mg
  • Oral solution 10mg/mL (Unlicensed)
08.03.01 Diethylstilbestrol 

Tablets 1mg, 5mg

Note:

Thrombosis may occur with diethylstilbestrol, concomitant aspirin 75mg may be
given. Fluid retention together with weight gain, gynaecomastia may occur.

Lowering of libido may occur during treatment.

02.01.01 Digoxin 
  • Tablets 62.5 micrograms, 125 micrograms, 250 micrograms
  • Elixir 50 micrograms/mL
  • Injection 250 micrograms/mL, 2mL ampoule (Hospital only)
18 Digoxin specific antibody fragments Digifab®

Digoxin Immune Fab - Injection, DigiFab® 40mg per vial (Hospital use only)

Notes:

  • For reversal of life-threatening digoxin overdose
  • Available on a named-patient basis only
  • Manufacturer has no out-of-hours service
04.07.02 Dihydrocodeine 

 Tablets 30mg     

02.06.02 Diltiazem (once daily dosing) 
  • Modified release capsules 120mg, 180mg, 240mg, 300mg (Zemtard XL)
  • Modified release capsules 200mg, 300mg (Tildiem LA) 
  • Please specify the brand when prescribing a modified release diltiazem preparation in order to avoid bioavailability differences. (This does not apply to the 60mg TDS tablet).
02.06.02 Diltiazem (three times daily dosing) 
  • Modified release generic tablets 60mg. Although labelled as MR, it is not slow-release and can be crushed for a small cohort of patients with swallowing difficulties in hospital.
  • Patients to be converted to BD or OD preparations on discharge if appropriate.
  • A once-a-day modified release preparation improves concordance.
  • There is no need for brand name prescribing.
02.06.02 Diltiazem (twice daily dosing) 
  • Modified release capsules 90mg, 120mg, 180mg (Adizem SR)
  • Modified release capsules 60mg, 90mg, 120mg (Dilcardia SR)
  • Modified release tablets 90mg, 120mg (Tildiem Retard)
  • Please specify the brand when prescribing a modified release diltiazem preparation in order to avoid bioavailability differences. (This does not apply to the 60mg TDS tablet).
01.07.04 Diltiazem 2% Cream/Ointment 

Cream 2% - unlicensed

Note: To be used when Glyceryl Trinitrate 0.4% rectal ointment is inappropriate or has failed. 

08.02.04 Dimethyl fumarate Tecfidera®

Tecfidera® Capsules 120mg, 240mg

 

13.05.02 Dimethyl Fumarate  Skilarence ®

Tablets gastro-resistant 30mg, 120mg 

07.04.04 DIMETHYL SULPHOXIDE Bladder Instillation 50% 
13.10.04 Dimeticone Hedrin®

Lotion, dimeticone 4%

Notes: 

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase
  • Dose: Rub into dry hair and scalp, allow to dry naturally, shampoo after minimum 8 hours (or overnight); repeat application after 7 days
07.01.01 Dinoprostone Prostin E2®

Prostin E2® Pessary Vaginal tablets 3mg
Propess® Vaginal delivery system 10mg
Prostin E2® IV injection 10mg/ml, 1mg/ml

use as per NICE clinical guideline 70 "induction of Labour" (July 2008)

08.02.04 Dinutuximab beta 

Qarziba® 20mg/4.5mL concentrate for solution for infusion

 

14.04 Diphtheria antitoxin 

 (Infanrix®-IPV+Hib, Pediacel®, Boostrix-IPV®, Infanrix IPV®, Repevax®, Revaxis®) 

13.02.01 Diprobase® 

Cream

02.09 Dipyridamole 
  • Tablets 25mg, 100mg
  • Modified release capsules 200mg (Persantin® Retard)
  • Suspension 50mg in 5mL

Notes:

  • The modified release capsules are licensed for secondary prevention of ischaemic stroke and transient ischaemic attacks, 1 capsule twice daily.
  • Dipyridamole is far more expensive than Aspirin and is licensed only as adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with prosthetic heart valves.
  • It has not been shown to be effective alone post-infarction or for TIAs.
  • Dipyridamole contributes little if anything to the anti-thrombotic action of Aspirin. This does not apply to Dipyridamole modified release preparation - Persantin® Retard.
02.03.02 Disopyramide 
  • Tablets - modified release 250mg 
  • Capsules 100mg
  • Injection 10mg/mL (5-mL amp) - Hospital only
13.05.02 Dithranol Dithrocream®

 Cream 0.1% to 2%

13.05.02 Dithranol Micanol®

 Cream 3%

British Association of Dermatologists accepted unlicensed dithranol preparations (extemporaneously prepared)

13.05.02 Dithranol Paste BP 

Dithranol 0.1% - 20%

  • in emulsifying ointment with salicylic acid 2%
  • in Lassar's paste

Note:

British Association of Dermatologists accepted unlicensed dithranol preparations (extemporaneously prepared)

02.07.01 Dobutamine 
  • Injection 12.5mg per 1ml (250mg in 20mL)
  • Injection 5mg per 1ml (250mg in 50mL)
08.01.05 Docetaxel Taxotere®

Concentrate for IV infusion 80mg in 2mL

Notes:
Dexamethasone by mouth 8mg bd for 3 days, starting on the day before each
course of docetaxel, is recommended for reducing fluid retention and
hypersensitivity reactions.

 

01.06.02 Docusate sodium 
  • Capsules 100mg
  • Paediatric oral solution - Sugar free 12.5mg/5mL
  • Adult oral solution - Sugar free 50mg/5mL 
05.03.01 Dolutegravir 

Tivicay® Tablets 50mg

05.03.01 Dolutegravir, abacavir & lamivudine Triumeq®

Abacavir 600mg / dolutegravir 50mg / lamivudine 300mg as Triumeq® Tablet film-coated

04.06 Domperidone 
  • Tablets 10mg
  • Oral suspension 5mg in 5mL

Notes

  • For short term use for nausea and vomiting only as per MHRA advice.
  • The maximum treatment duration should not exceed one week
  • Domperidone is now contraindicated in people:
    ◦With conditions where cardiac conduction is, or could be, impaired
    ◦With underlying cardiac diseases such as congestive heart failure
    ◦Receiving other medications known to prolong QT interval or potent CYP3A4 inhibitors
    ◦With severe hepatic impairment
04.11 Donepezil 
  • Tablets 5mg, 10mg
  • Orodispersible tablets 5mg, 10mg

 

Note: Only use dispersible tablets where the patient has proven swallowing difficulties. 

02.07.01 Dopamine 
  • Injection 200mg in 5mL
  • Injection 800mg in 5mL 
11.06 Dorzolomide Trusopt®
  • Ophthalmic solution 2% 
  • Single use eye drops 2%
11.06 Dorzolomide 2% with Timolol 0.5% Cosopt®

Ophthalmic solution: dorzolamide 2%, timolol 0.5%

Note: 

  • Cosopt® has been included to aid compliance for those patients requiring both a carbonic anhydrase inhibitor and beta-blocker.  
04.03.01 Dosulepin 

Note: Classed as a "Low Value Medicine"

  • Capsules 25mg
  • Tablets 75mg

 Dosulepin Commissioning Statement:

  • Prescribers should not initiate Dosulepin for any new patient.
  • Dosulepin should be discontinued from primary care prescribing (deprescribed), with support from specialist services if necessary.
  • If, in exceptional circumstances, (where the prescribing clinician considers no other medicine or intervention is clinically appropriate and available for the individual) there is a clinical need for dosulepin to be prescribed in primary care, this should be undertaken in a cooperation agreement with a multi-disciplinary team and/or other healthcare professional.
  • Patient Information Leaflet can be found on the formulary website at: 

Changes to dosulepin prescribing

13.02.01 DoubleBase® 

Cream

03.05.01 Doxapram Dopram®
  • Injection 20mg/ml (100mg in 5 ml amp)
  • Infusion 2mg/ml in 5% glucose (1g in 500ml)
07.04.01 Doxazosin 

Tablets 1mg, 2mg, 4mg

08.01.02 Doxorubicin 

Injection 10mg in 5ml, 50mg in 25ml vial

08.01.02 Doxorubicin hydrochloride pegylated liposomal Caelyx®

Caelyx® Injection, 2mg/mL concentrate for solution for infusion

 

05.01.03 Doxycycline 

Capsules 50mg, 100mg

13.06.02 Doxycycline 
  • capsules 50mg, 100mg

 

02.03.02 Dronedarone 

Tablets 400mg

Notes

  • For Consultant Cardiologist use or recommendation only
06.01.02.03 Dulaglutide Trulicity®

Trulicity® Injection 0.75mg, 1.5mg

Notes:

04.03.04 Duloxetine 

Capsules 30mg, 60mg

Note: Restricted for use by Consultant Psychiatrist only.

04.07.03 Duloxetine 

(Off-label indication)

Capsules 30mg, 60mg

04.07.04.02 Duloxetine 

(Off-label indication)

Capsules 30mg, 60mg

13.05.03 Dupilumab Dupixent®

300mg/2ml solution for injection pre-filled syringes 

08.01 Durvalumab 

Imfinzi® 50 mg/mL concentrate for solution for infusion

 

02.08.02 Edoxaban Lixiana®

Tablets film-coated 15mg, 30mg, 60mg 

Notes:

  • Edoxaban represents the most cost-effective DOAC for many patients. Refer to the local guideline above before prescribing.
10.02.01 Edrophonium chloride 

Injection 10mg in 1 ml

Used as diagnostic agent for myasthenia gravis.

05.03.01 Efavirenz 
  • Tablets film-coated 600mg
  • Sustiva® Capsules 50mg, 100mg, 200mg
05.03.03.02 Elbasvir/Grazoprevir Zepatier®

Tablets film-coated 50mg/100mg

09.01.04 Eltrombopag Revolade®

Tablets 25mg, 50mg

Advice for healthcare professionals:


• Eltrombopag is highly coloured (reddish-brown) and can cause serum discolouration and interference with the test results of creatinine and bilirubin.


• Be aware that interference with bilirubin (falsely low/normal results) and creatinine (falsely high/normal results) may occur in patients taking eltrombopag.


• If bilirubin and/or creatinine laboratory results are inconsistent with clinical observations, request re-testing using another method to determine the validity of the result.


• The laboratory may consider susceptibility to serum discolouration and other factors that may be relevant when selecting an alternative test method.


• Report suspected adverse drug reactions, including any harm that
occurs from a medicine interfering with laboratory test results, to the Yellow Card Scheme.

01.04.02 Eluxadoline Truberzi®

Tablets film-coated 100mg

 

06.01.02.03 Empagliflozin Jardiance®

Jardiance® Tablets 10mg, 25mg

06.01.02.03 Empagliflozin and Metformin Synjardy®

Synjardy® Tablets f/c 5mg/850mg, 5mg/1000mg, 12.5mg/850mg,
12.5mg/1000mg

 

05.03.01 Emtricitabine Emtriva®
  • Capsules 200mg
  • Oral solution sugar free, 10mg/mL
05.03.01 Emtricitabine + rilpivirine + tenofovir alafenamide Odefsey®

Tenofovir alafenamide 25mg (as fumarate) / rilpivirine
25mg/emtricitabine 200mg Odefsey® Tablet film-coated

05.03.01 Emtricitabine + tenofovir alafenamide ( as fumarate) Descovy®
  • Tablet film-coated, 10mg / 200mg
  • Tablet film-coated, 25mg / 200mg
05.03.01 Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg Eviplera®

Tenofovir disoproxil 245mg (as fumarate) / rilpivirine 25mg / emtricitabine 200mg, tablet film-coated

13.02.01 Emulsifying Ointment BP 

Ointment

02.05.05.01 Enalapril maleate 

Tablets 2.5mg, 5mg, 10mg, 20mg

08.01.05 Encorafenib Braftovi®

Capsule 300mg

 

05.03.01 Enfuvirtide Fuzeon®

Injection 108mg

Note:
90 mg/ml powder and solvent for solution for injection.
Each vial contains 108 mg enfuvirtide.
Each ml of reconstituted solution contains 90 mg enfuvirtide.

02.08.01 Enoxaparin sodium Inhixa®

100 mg/mL (equivalent to 10,000 units anti-Factor Xa activity) solution in single dose pre-filled syringes

 

  • Injection 20mg in 0.2mL pre-filled syringe
  • Injection 40mg in 0.4mL pre-filled syringe
  • Injection 60mg in 0.6mL pre-filled syringe
  • Injection 80mg in 0.8mL pre-filled syringe
  • Injection 100mg in 1mL pre-filled syringe

 

Notes:

  • For use in Maternity patients only
  • Discharge supplies - Patients with GPs in MK are supplied 14 days of enoxaparin on discharge and GP is expected to continue therapy.
04.09.01 Entacapone 

  Tablets 200mg

05.03.03.01 Entecavir Baraclude®
  • Tablets 500micrograms, 1mg
  • Oral solution 50micrograms/mL

Note:

  • Entecavir should be used second-line for Chronic Hepatitis B in cases of treatment failure or pre-selected resistance to Tenofavir.
08.03.04.02 Enzalutamide Xtandi®

Capsules 40mg

 

02.07.02 Ephedrine 
  • Injection 3mg in 1mL (30mg/10ml pre-filled syringes)
  • Injection 30mg in 1mL (ampoules)
03.01.01.02 Ephedrine Hydrochloride 

Ephedrine hydrochloride

  • Injection 30mg in 1mL
12.02.02 Ephedrine hydrochloride 

Nasal drops 0.5%, 1%      

Notes:

  • Topical nasal decongestants containing sympathomimetics, ephedrine and xyometazoline, can cause rebound congestion following prolonged use (more than 7 days) and are therefore of limited value.
  • Ephedrine nasal drops should be used with caution in infants under 3 months of age. There is no good evidence of value – if irritation occurs it might narrow the nasal passage.       
08.01.02 Epirubicin hydrochloride 

Injection 10mg in 5ml vial, 50mg in 25ml vial

02.02.03 Eplerenone 

Tablets 25mg, 50mg

Notes:

  • For use with standard therapy, to reduce risk of cardiovascular mortality and morbidity in stable patients with LVD (LVEF ≤40%) and clinical evidence of heart failure after recent MI or in patients with LVD (LVEF ≤30%) and chronic heart failure (NYHA II).
  • Therapy should be started within 3-14 days of event.
  • Eplerenone may be useful when patients have symptomatic gynaecomastia.
  • Plasma potassium levels should be checked before eplerenone is started, during the first week of treatment, and a month after starting. It is expected that treatment will be commenced within PHNT. GPs will then be asked to review potassium levels after one month of treatment and adjust the dose according to the table below:

 

Serum Potassium (mmol/L)

Action

Dose adjustment

< 5

Increase

25mg alternate days to 25mg OD

25mg OD to 50mg OD

 5.0 – 5.4

Maintain

No dose adjustment

5.5 – 5.9

Decrease

50mg OD to 25mg OD

25mg OD to 25mg alternate days

25mg alternate days to withhold

≥ 6.0

Withhold

N/A

 

  • Serum potassium should be assessed as needed periodically thereafter.
  • Elderly patients, diabetics, those with mild renal failure or mild to moderate hepatic failure should be monitored more frequently to ensure that normal potassium levels are maintained.
09.01.03 Epoetin alfa Eprex®
  • Eprex® Injection, prefilled syringes - 1000, 2000, 3000, 4000, 5000, 6000, 8000, 10 000, 20 000, 30 000, 40 000 units
  • Eprex® [Amber 3] - Eprex can be prescribed by GPs after consultant initiation and stabilisation. However, renal patients remain under hospital prescribing and Eprex should NOT be prescribed by their GP.
09.01.03 Epoetin beta NeoRecormon®

NeoRecormon® Injection, prefilled syringes – 500, 2000, 3000, 4000, 5000, 6000, 10,000, 20,000, 30,000 units 

02.08.01 Epoprostenol Flolan®

Consultant request only

Flolan® Infusion, powder for reconstitution 500 micrograms vial with diluent    

09.06.04 Ergocalciferol 

Injection 300,000 units in 1mL

07.01.01 Ergometrine Maleate 

Injection 500micrograms in mL

07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®

Injection containing ergometrine maleate 500micrograms and oxytocin 5 units in 1 mL

08.01.05 Eribulin Halaven®

Halaven® Injection, 0.44mg/mL solution in vial

 

08.01.05 Erlotinib Tarceva®

Tarceva® Tablet film coated 25mg, 100mg, 150mg

 

05.01.02.02 Ertapenem Invanz®

Injection 1g

Note:

Ertapenem is restricted for use for the Outpatient Parenteral Antibiotic Therapy (OPAT) service after approval from consultant microbiologist.

06.01.02.03 Ertugliflozin Steglatro®

Steglatro® Tablets 5mg, 15mg

05.01.05 Erythromycin 
  • Tablets 250mg
  • Oral suspension sugar free (ethylsuccinate) 125mg/5mL, 250mg/5mL
    500mg/5mL
05.01.05 Erythromycin 

Injections 1 gram

13.06.02 Erythromycin 
13.06.01 Erythromycin 40mg with Zinc Acetate 12mg/mL Zineryt®

Topical solution

04.03.03 Escitalopram 

Tablet 5mg, 10mg, 20mg

Note:  Only for initialtion by Consultant Psychiatrist where other treatments have failed.

 

Advice for healthcare professionals:

Maximum daily dose schedule is as follows:

  Adults Adults >65 years Adults with hepatic impairment
Citalopram 40 mg* 20 mg* 20 mg*
Escitalopram 20 mg 10 mg* 10 mg

*New (restricted) maximum daily dose.

Contraindications in patients at greatest risk of QT interval prolongation:

Citalopram and escitalopram should not be used:

    • in patients with congenital long QT syndrome or known pre-existing QT interval prolongation
    • in combination with other medicines known to prolong the QT interval

 

02.04 Esmolol 

Injection 10mg/mL (10mL vial) - For testing for suitability for beta blockade only.

01.03.05 Esomeprazole 

Capsules 20mg, 40mg

06.04.01.01 Estradiol  Sandrena®

Estradiol 500 microgram, 100 microgram gel as Sandrena®

For topical use

06.04.01.01 Estradiol Elleste-Solo®

Estradiol 1mg, 2mg tablets as Elleste Solo®

Unopposed oestrogen (if uterus is intact an adjunctive progestogen must be used), hysterectomy

Prescription charge - 1

06.04.01.01 Estradiol Evorel®

Estradiol 25 microgram, 50 microgram, 75 microgram, 100 microgram Patches as Evorel®

Unopposed oestrogen (if uterus is intact an adjunctive progestogen must be used), hysterectomy

Prescription charge - 1

06.04.01.01 Estradiol FemSeven®

Estradiol 50 microgram, 75 microgram, 100 microgram Patches as FemSeven® (Amber 2)

Unopposed oestrogen (if uterus is intact an adjunctive progestogen must be used), hysterectomy

Prescription charge - 1

06.04.01.01 Estradiol  Elleste Solo MX®

Estradiol 40 microgram, 80 microgram patches as Elleste Solo MX® (Amber 2)

Unopposed oestrogen (if uterus is intact an adjunctive progestogen must be used), hysterectomy

Prescription charge - 1

If skin allergy / poor absorption with Evorel (contains alternative advesive)

06.04.01.01 Estradiol / Dydrogesterone  Femoston Conti®

Estradiol 500 microgram / Dydrogesterone 2.5mg tablets

Estradiol 1mg / Dydrogesterone 5mg tablets

Prescribe as Femoston Conti® (Amber2)

Continuous combined therapy

Uterus present, post menopausal women, cycle free

No bleed

Prescription charge -1

06.04.01.01 Estradiol / Dydrogesterone Femoston®

Estradiol 1mg tablets and Estradiol 1mg / Dydrogesterone 10mg tablets

Estradiol 2mg tablets and Estradiol 2mg / Dydrogsterone 10mg tablets

Prescribe as Femoston® (Amber 2)

Sequential/Cyclical combined therapy

Uterus present, perimenopausal women, cycle free

Monthly bleed

Prescription charge -2

For use if cyclical side effects with norethisterone or other progestogen

06.04.01.01 Estradiol / Medroxyprogesterone  Tridestra®

Estradiol 2mg tablets and Estradiol 2mg / Medroxyprogesterone 20mg tablets as Tridestra® (Amber 2)

Sequential/Cyclical combined therapy

Uterus present, perimenopausal women, cycle free

Quaterly bleed

Prescription charge -2

For women where a longer bleed interval is useful.

06.04.01.01 Estradiol / Norethisterone Evorel® Sequi

Estradiol 50 mcg patches and Estradiol 50 mcg / Norethisterone 170mcg patches as Evorel Sequi®

Sequential/Cyclical combined therapy

Uterus present, perimenopausal women, cycle free

Monthly bleed

Prescription charge -2

06.04.01.01 Estradiol / Norethisterone Elleste-Duet®

Estradiol 1mg tablets and Estradiol 1mg / Norethisterone 1mg tablets

Estradiol 2mg tablets and Estradiol 2mg / Norethisterone 1mg tablets

Prescribe as Elleste Duet®

Sequential/Cyclical combined therapy

Uterus present, perimenopausal women, cycle free

Monthly bleed

Prescription charge -2

06.04.01.01 Estradiol 1mg / Norethisterone 500 mcg Kliovance®

Estradiol 1mg / Norethisterone 500 mcg tablets as Kliovance®

Continuous combined therapy

Uterus present, post menopausal women, cycle free

No bleed

Prescription charge -1

 

06.04.01.01 Estradiol 2mg / Norethisterone 1mg  Kliofem®

Estradiol 2mg / Norethisterone 1mg tablets as Kliofem®

Continuous combined therapy

Uterus present, post menopausal women, cycle free

No bleed

Prescription charge -1

06.04.01.01 Estradiol 50 mcg / Norethisterone 170 mcg Evorel® Conti

Estradiol 50 mcg / Norethisterone 170 mcg patches as Evorel Conti® (Amber 2)

Continuous combined therapy

Uterus present, post menopausal women, cycle free

No bleed

Prescription charge -1

10.01.03 Etanercept Enbrel®

25mg in 0.5ml pre-filled syringe, 25mg injection

10.01.03 Etanercept Benepali®

50mg in 1ml pre-filled syringes

13.05.03 Etanercept Enbrel®

Injection, 25mg, 50mg solution in pre-filled syringe or pre-filled pen 

Injection, 10mg powder and solvent for solution in vial for paediatric use

09.05.01.02 Etelcalcetide Parsabiv®

Solution for injection; 2.5mg, 5mg, 10mg in vial

05.01.09 Ethambutol  

Tablets 100mg, 400mg


Suspension 400mg in 5ml, unlicensed; prescribers are to restrict
prescribing to this strength

06.04.01.01 Ethinylestradiol 

Tablets 2 micrograms, 10 micrograms, 50 micrograms, 1mg

Notes:
Tablets 10 micrograms, 50 micrograms, 1mg, 2 microgram unlicensed special.

Licensed for short term treatment of oestrogen deficiency, female
hypogonadism and menstrual disorders.

Ethinylestradiol tablets are very expensive consider using oestradiol where
clinically appropriate as a more cost effective option.

Ethinylestradiol is included for the specialist treatment of hereditary
haemorrhagic telangiectasia.

07.03.01 Ethinylestradiol / etonogestrel Vaginal Delivery System NuvaRing®

Releases ethinlyestradiol 15 microgram & etonogestrel 120 microgram per 24hrs over a period of 3 weeks as NuvaRing® (Amber 2) 

Use restricted to patients unable to use other methods of contraception and for prescribing by specialists in contraceptive health.

07.03.01 Ethinylestradiol / Levonorgestrel phased pill 

Ethinylestradiol 30 microgram and Levonorgestrel 50 microgram

Ethinylestradiol 40 microgram and Levonorgestrel 75 microgram

Ethinylestradiol 30 microgram and Levonorgestrel 125 microgram

28 day phasic preparation

as Logynon® ED

07.03.01 Ethinylestradiol / levonorgestrel phased pill Logynon

Ethinylestradiol 30 microgram and Levonorgestrel 50 microgram

Ethinylestradiol 40 microgram and Levonorgestrel 75 microgram

Ethinylestradiol 30 microgram and Levonorgestrel 125 microgram

21 day phasic preparation

as Logynon®

 

07.03.01 Ethinylestradiol 20 mcg / gestodene 75 mcg 

Ethinylestradiol 20 mcg / gestodene 75 mcg

21 day monophasic preparation

Aidulan® 20/75 is cost effective choice

Millinette® 20/75

Femodette® is alternative brand (Amber 2)

07.03.01 Ethinylestradiol 20 mcg / norethisterone 1mg 

Ethinylestradiol 20 mcg / norethisterone 1mg as Loestrin® 20

 

21 day monophasic preparation

 

07.03.01 Ethinylestradiol 20mcg / desogestrel 150mcg 

Ethinylestradiol 20mcg / desogestrel 150mcg

21 day monophasic preparation

Munalea® 20/150 is a cost effective choice

Gedarel® 20/150

Alternative brand Mercilon® (Amber 2)

07.03.01 Ethinylestradiol 30 mcg / drospirenone 3 mg 

Ethinylestradiol 30 mcg / drospirenone 3 mg

21 day monophasic preparation

Yinzell® and Lucette® are cost effective equivalents to Yasmin®

All to be used 3rd or 4th line for women intolerant to other contraceptives

07.03.01 Ethinylestradiol 30 mcg / Gestodene 75 mcg 

Ethinylestradiol 30mcg / Gestodene 75 mcg as Femodene ED®

28 day monophasic preparation

07.03.01 Ethinylestradiol 30 mcg / Levonorgestrel 150 mcg 

Ethinylestradiol 30 mcg / Levonorgestrel 150 mcg as Microgynon 30 ED®

28 day monophasic preparation

07.03.01 Ethinylestradiol 30 mcg / Norethisterone acetate 1.5mg 

Ethinylestradiol 30 mcg / Norethisterone acetate 1.5mg as Loestrin® 30

21 day monophasic preparations

07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg 

Ethinylestradiol 30mcg / desogestrel 150mcg

21 day monophasic preparation

Munalea® 30/150 is cost effective choice

Gedarel® 30/150

Marvelon® (Amber 2) is alternative brand

07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg 

Ethinylestradiol 30mcg / gestodene 75 mcg

21 day monophasic preparation

Aidulan® 30/75 is cost effective choice

Millinette® 30/75

Femodene® is alternative choice (Amber 2)

07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg 

Ethinylestradiol 30mcg / levonorgestrel 150mcg

21 day monophasic preparations

Maexeni® is cost effective choice

Rigevidon®

Alternative brands (Amber 2) are Microgynon® and Ovranette®

07.03.01 Ethinylestradiol 35 mcg / noresthisterone 1mg 

Ethinylestradiol 35 mcg / noresthisterone 1mg as Norimin®

21 day monophasic preparations

07.03.01 Ethinylestradiol 35 mcg / noresthisterone 500mcg 

Ethinylestradiol 35 mcg / noresthisterone 500mcg as Brevinor®

21 day monophasic preparations

 

07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg 

Ethinylestradiol 35 mcg / norgestimate 250 mcg

21 day monophasic preparations

Cilique® is cost-effective choice

Cilest® is alternative brand (Amber 2)

07.03.01 Ethinylestradiol/ norelgestromin patch Evra®

Ethinylestradiol 33.9 microgram in 24hrs and norelgestromin 203 microgram in 24 hrs as Evra® Patch (Amber 2)

 

May be of value in women who are poor compliers with oral contraceptives. Women should have tried at least 2 oral contraceptives.

08.03.01 Ethinylestradol 

Tablets 10 micrograms, 50 micrograms, 1mg

15.01.01 Etomidate Etomidate-Lipuro®
  • 20mg/10mL amps

Note:

  • Etomidate does cause adrenal suppression.
07.03.02.02 Etonogestrel 68mg 

Etonogestrel 68mg implant as Nexplanon®

Long acting reversible contraception

Subdermal implant whihh offers contraception for 3 years

08.01.04 Etoposide 

Concentrate for IV infusion 100mg in 5mL, 500mg in 25mL
Capsules 50mg, 100mg

05.03.01 Etravirine Intelence®

Tablets 25mg, 100mg, 200mg

04.08.01 Everolimus Votubia®
  • 2.5mg, 5mg, 10mg
  •  dispersible 2mg, 3mg, 5mg

Notes:

  • Use must be registered on the Blueteq system  
  • Funded by NHS England
08.01.05 Everolimus Afinitor®

Afinitor® Tablets 2.5mg, 5mg, 10mg
Certican® Tablets 250 microgram, 750 microgram

 

02.12 Evolocumab Repatha®

140mg/mL solution for injection; pre-filled syringe 1x1mL, pre-filled SureClick pen 2x1mL

08.03.04.01 Exemestane 

Tablets 25mg

 

06.01.02.03 Exenatide Byetta®

Byetta® Injection 250mcg/mL

02.12 Ezetimibe 

Tablets 10mg 

 

05.03.02.01 Famciclovir 

Tablets 125mg, 250mg, 500mg

10.01.04 Febuxostat Adenuric®

Tablets 80mg, 120mg

02.06.02 Felodipine 

Tablets modified release 2.5mg, 5mg, 10mg 

02.12 Fenofibrate 
  • Capsules 67mg, 200mg, 267mg
  • Tablets 160mg
04.07.02 Fentanyl 
  • Patch 12 microgram/hour, for 3 days
  • Patch 25 microgram/hour, for 3 days
  • Patch 50 microgram/hour, for 3 days
  • Patch 75 microgram/hour, for 3 days
  • Patch 100 microgram/hour, for 3 days

In primary care, fentanyl patches should be prescribed as Fencio brand.

04.07.02 Fentanyl Effentora® buccal tablets

Buccal tablets 100micrograms, 200micrograms, 400micrograms 

Prescribing on the recommendation of Palliative Care only. 

Must be initiated and stabilised by the specialist in Palliative Care prior to passing prescribing responsibility to the GP.

 

Fentanyl, Immediate Release Commissioning Statement

The statement below applies to prescribing outside NICE CG140 Opioids in Palliative Care.

Prescribers should not initiate immediate release fentanyl for any new patient other than in line with NICE CG140 Opioids in Palliative Care.

If necessary, immediate release fentanyl should be discontinued from primary care prescribing (deprescribed) with support from specialist services.

Patient Information Leaflet can be found on the formulary website at https://www.formularymk.nhs.uk/includes/documents/Patient-information-Changes-to-immediate-release-fentanyl-prescribing.pdf

15.01.04.03 Fentanyl 
  • 100 micrograms in 2mL amp
  • 500 micrograms in 10mL amp

Note: Intravenous use by anaesthetists and intensive care physicians only due to rapid and profound respiratory depression. Intravenous fentanyl Patient Controlled Analgesia (PCA) may only be prescribed on the advice of an anaesthetist or the Acute Pain Team.

09.01.01.02 Ferric Carboxymaltose Ferinject®

Injection 50mg/mL

09.01.01.01 Ferric maltol Feraccru®

Capsules 30mg

Notes:

  • Second line for iron deficiency anaemia in adult with mild to moderate IBD who have failed 2 oral ferrous products.
  • To be considered prior to administration of IV options.
  • Usual duration - 12 weeks.
09.01.01.01 Ferrous Fumarate 
  • Tablets 210mg (equivalent to 68mg ferrous iron per tablet) 
  • Syrup 140mg/5mL (equivalent to 45mg ferrous iron per 5mL)
09.01.01.01 Ferrous Sulfate 

Tablets 200mg (equivalent to 65mg ferrous iron per tablet)

Note:

Iron preparations differ in their iron content. As gastro-intestinal side effects are related to the iron content there is a lower incidence of side effects with preparations containing less iron.

16.01 Ferucarbotran  Resovist

Pre-filled syringes 1.4 ml

03.04.01 Fexofenadine hydrochloride 

Tablets 120mg for seasonal allergic rhinitis - for use only after failure of other over the counter (OTC) antihistamines.

Tablets 180mg for chronic idiopathic urticaria

05.01.07 Fidaxomicin Dificlir®

Tablets 200mg

Note:  On recommendation of a consultant microbiologist only.

09.01.06 Filgrastim Neupogen®

Injection 30 million units (300 micrograms) in 1mL vial or pre-filled syringe

09.01.06 Filgrastim Zarzio®, Accofil®
  • Injection 30 million units (300 micrograms) in 0.5mL pre-filled syringe
  • Injection 48 million units (480 micrograms) in 0.5mL pre-filled syringe
06.04.02 Finasteride 

Tablet 5mg

13.09 Finasteride (Double Red - not approved for use within MK) Propecia®
  • Propecia® Tablets film-coated 1mg

Notes: 

06.01.01.03 FinePoint 
08.02.04 Fingolimod 

Gilenya® Capsules 500mcg

 

02.03.02 Flecainide 
  • Tablets 50mg, 100mg - Amber 3
  • Injection 10mg/mL (15-mL amp) - For use in life-threatening arrhythmias only 
13.04 Flucinolone 0.025% Synalar®
  •  0.025% ointment, 250 microgram per 1 gram
  • 0.025% cream, 250 microgram per 1 gram
05.01.01.02 Flucloxacillin 

Capsules 250mg, 500mg

Oral solution 125mg/5ml, 250mg/5ml

Injection 250mg, 1gram

05.02 Fluconazole 
  • Capsules 50mg, 150mg, 200mg
  • Oral suspension 10mg/1ml, 40mg/1ml
  • Infusion 200mg/100ml (Hospital Only)
07.02.02 Fluconazole 

Capsules 150mg

08.01.03 Fludarabine Phosphate Fludara®

Tablets 10mg
Injection, powder for reconstitution 50mg vial

 

06.03.01 Fludrocortisone 

Tablets 100 micrograms

 

Fludrocortisone may be given as a mineralocorticoid in combination with
hydrocortisone in adrenocortical insufficiency.


Use can be made of the mineralocorticoid activity of fludrocortisone in the
treatment of neuropathic postural hypotension. (Unlicensed indication)

15.01.07 Flumazenil 

 500micrograms in 5mL amp

12.01.01 Flumetasone 0.02% with Clioquinol 1% 

Ear drops: flumetasone pivalate 0.02%, clioquinol 1%

11.04.01 Fluocinolone acetonide intravitreal implant Iluvien®

Iluvien® Intravitreal implant containing fluocinolone acetonide 190 micrograms in a disposable applicator

11.08.02 Fluorescein Anatera®
  • Single use eye drops 2%
  • Ophthalmic strip
  • Injection 20% (unlicensed)

Notes:

  • Fluorescein sodium is the standard preparation to detect ocular lesions and foreign bodies.
  • It is used in both primary and secondary care clinic settings and it should not be prescribed for patients as it is used for diagnostic purposes only.
11.04.01 Fluorometholone FML®

Ophthalmic suspension 0.1% 

08.01.03 Fluorouracil 

Capsules 250mg (named patient only) U

Injection 250mg/10ml vial

13.08.01 Fluorouracil Efudix®
04.03.03 Fluoxetine 
  • Capsules 20mg
  • Liquid 20mg in 5ml
04.02.01 Flupentixol 
  • Depixol® Tablets 3mg
  • Fluanxol® Tablets 500 microgram, 1mg
04.02.02 Flupentixol Decanoate Depixol®

Diluent = Coconut oil

  •  Injection 20mg/mL - 20mg in 1mL, 40mg in 2mL
  •  Injection 100mg/mL ("Concentrate") - 50mg in 0.5mL, 100mg in 1mL
  •  Injection 200mg/mL ("Low-volume") - 200mg in 1mL 
10.01.01 Flurbiprofen 

Tablet 50mg

11.08.02 Flurbiprofen Ocufen®

Ophthalmic solution 0.03%

08.03.04.02 Flutamide 

Tablets 250mg

Note:
Flutamide is given to counter tumour flare with initial gonadorelin therapy.

Used for up to 3 weeks in patients with symptomatic and advanced prostatic
carcinoma only.

12.02.01 Fluticasone furoate Avamys®

 Nasal spray, 27.5 micrograms per spray  

Notes:

  • Avamys to be used for allergic rhinitis.
03.02 Fluticasone furoate & vilanterol Relvar Ellipta®

92mcg fluticasone furoate/22mcg vilanterol (as trifenatate) - licensed for Asthma & COPD (DPI)

184mcg fluticasone furoate/22mcg vilanterol (as trifenatate) - licensed for Asthma only (DPI)

 

Notes: Combined preparations reduce the flexibility of the individual components and are therefore not suitable for unstable asthmatics.

The prescribing advisory group does NOT recommend the use of new products containing fluticasone for asthma. Our agreed strategy is to move away from fluticasone where possible in order to ensure that patients are stepped down and doses do not exceed those recommended by the MHRA.

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar.

03.02 Fluticasone furoate, umeclidinium & vilanterol inhaler Trelegy Elipta®

Vilanterol 22micrograms / Fluticasone 92 micrograms/ Umeclidinium 55 micrograms dose (Trelegy Elipta Inhaler DPI)

Notes: COPD patients with NO asthmatic features should be referred to AIRS / PCOC service before considering Triple Therapy Inhalers in line with the NEW COPD guidance.

03.02 Fluticasone propionate Flixotide®

MDI inhaler 50, 125, 250 micrograms/dose

Accuhaler (DPI) 50, 100, 250 micrograms/dose

 

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect.The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar 

12.02.01 Fluticasone Propionate Flixonase®

 Nasal spray, 50 micrograms per spray  

Notes: 

  • Flixonase to be used for perennial rhinitis.
12.02.01 Fluticasone Propionate Flixonase Nasule®
  •  Nasule Drops ,400 micrograms (1 mg/ml), nasal drops suspension.

Notes:

      for the treatment of nasal polyps only.

03.02 Fluticasone propionate and salmeterol Seretide

Accuhaler (DPI) 100, 250, 500

Evohaler (MDI) 50, 125, 250

Notes:

  • The higher doses (Seretide Accuhaler 250 and 500, Evohaler 125 and 250) are only advised in step 4 of the management of asthma in adults
  • Seretide Accuhaler is licensed for COPD but the Evohaler is not - many patients with COPD are using the Seretide 250 Evohaler.  The cost of Seretide Accuhaler 500 (One Puff bd) is significantly less than Seretide 250 Evohaler (Two Puffs bd)

Inhaled Cortocosteroids (ICS) - Important notes:
The lowest possible dose should be prescribed to maintain therapeutic effect. The total daily dose of inhaled corticosteroids should rarely be increased above:
Children: 800 micrograms beclometasone or budesonide; 400 micrograms fluticasone.
Adults: 2000 micrograms beclometasone or budesonide; 1000 micrograms fluticasone or Qvar. 

03.01.05 Flutter Device

This device has been replaced by the Aerobika® device (oscillating positive expiratory pressure system).

19 Foam Lite™ ConvaTec

5cm x 5cm

5.5cm x 12cm

6cm x 8cm

10cm x 10cm

10cm x 20cm

15cm x 15cm

Foam Lite company web site

 

09.01.02 Folic Acid 
  • Tablets 5mg
  • Tablets 400 microgram  
  • SyrupSF2.5mg in 5mL
  • SyrupSF 400 microgram in 5mL 
  • Folic Acid – injection 15mg/mL  U  

Care should be taken in giving folic acid on its own for megaloblastic anaemia. Patients given folic acid alone must have a proven high/normal B12 level before folic acid is started or else both must be given jointly until the level has back, if there is an urgent need to start treatment.

A ferritin level should also be done before treatment is given and one month after starting in case there is an occult iron deficiency which may become evident afetr B12 and folate replacement.

Neural tube defects (prevention in preganancy)

Periconceptional Folic Acid and Food Fortification in the Prevention of Neural Tube Defects (SAC Opinion Paper 4)

Recommendations of an expert advisory group of the Department of Health include the advice that:

  • To prevent recurrence of neural tube defect (in a child of a man or woman with spina bifida, or if there is a history of neural tube defect in a previous child). Women who wish to become pregnant (or who are at risk of becoming pregnant) should be advised to take folic acid supplements at a dose of 5mg daily (reduced to 4mg daily if a suitable preparation becomes available). Supplementation should continue until the twelfth week of pregnancy. Women receiving antiepileptic therapy need individual counselling by their doctor before starting folic acid.
  • To prevent first occurrence of neural tube defect women who are planning a pregnancy should be advised to take folic acid as a medicinal or food supplement at a dose of 400 micrograms daily before conception and during the first 12 weeks of pregnancy. Women who have not been supplementing and who suspect they are pregnant should start at once and continue until the twelfth week of pregnancy.
  • There is no justification for prescribing multiple-ingredient vitamin preparations containing vitamin B12 or folic acid.
08.01 Folinic acid 

Tablets 15mg (Calcium Folinate)
Injection 7.5mg/mL (2mL amp)

02.08.01 Fondaparinux sodium Arixtra®

Arixtra® Injection 2.5mg/0.5mL in pre-filled syringes

Notes:

  • For treatment of unstable angina or non-ST segment elevation myocardial infarction in adults for whom urgent (< 120 mins) invasive management (PCI) is not indicated.
  • For Hospital prescribing only and for a maximum of 8 days or till hospital discharge if that occurs earlier.
03.01.01.01 Formoterol  
  • Easyhaler Dry powder for inhalation, 12 micrograms per metered inhalation

          Formoterol Easyhaler® preferred as more cost effective device

  • Oxis Dry powder for inhalation (DPI), 6 micrograms per metered inhalation, 12 micrograms per metered inhalation
03.01.01.01 Formoterol Fumarate Atimos® Modulite

Atimos modulite Aerosal inhaltion, 12 micrograms/metered inhalation

MDI - (Metered Dose Inhaler) 

Licensed 6 years and above

 

Formoterol Easyhaler® preferred as more cost effective.

03.02 Formoterol fumarate, beclometasone dipropionate and glycopyrronium bromide  Trimbow®

Beclometasone 87mcg / Formoterol 5mcg / Glycopyrronium 9mcg (Trimbow MDI inhaler)

Notes: COPD patients with NO asthmatic features should be referred to AIRS / PCOC service before considering Triple Therapy Inhalers in line with the NEW COPD guidance.

05.01.07 Fosfomycin 
  • Monuril® Granules, 3g oral sachet
  • Fomicyt® Intravenous Infusion, powder for reconstitution, 2g, 4g vials

Note:

For the treatment of Uncomplicated Cystitis with ESBL-producing organisims.

06.01.06 FreeStyle Libre® 
02.02.02 Furosemide 
  • Tablets 20mg, 40mg, 500mg
  • Oral solution - Sugar free 20mg/5mL, 40mg/5mL, 50mg/5mL
  • Injection 20mg/2mL, 50mg/5mL, 250mg/25mL (Hospital only)

Note:

Furosemide is the first line choice. Bumetanide may be better absorbed than furosemide in patients with severe CCF.

11.03.01 Fusidic Acid 

Viscous eye drops 1% (Contains: benzalkonium chloride, disodium edetate)  

 Notes:

  • Fusidic acid should be reserved for people who:
    - Are pregnant.
    - Have a personal or family history of blood dyscrasias, such as aplastic anaemia.
    - Are intolerant of chloramphenicol.
    - Need a twice-a-day treatment for infective conjunctivitis
    See CKS topic for more information.
  • Jan 2016: price increased from £2 a tube to £35 a tube!
13.10.01.02 Fusidic Acid 2% topical Fucidin®

Cream / Ointment 2%  

Notes:      

  • Topical fusidic acid is included for 2nd line treatment of impetigo 
04.07.03 Gabapentin 

Capsules 100mg, 300mg 400mg

04.07.04.02 Gabapentin 

(Off-label indication)

  • Capsules 100mg, 300mg 400mg
  • Tablets 600mg, 800mg
  • Oral solution 50mg/ml
04.08.01 Gabapentin 
  • Capsule 100mg, 300mg, 400mg
  • Tablets 600mg, 800mg  
04.11 Galantamine 
  • Capsules, Modified Release 8mg, 16mg, 24mg
  • Tablets 8mg, 12mg
  • Oral solution 4mg/mL
05.03.02.02 Ganciclovir 

Injection 500mg vial

11.03.03 Ganciclovir eye gel Virgan®

Ophthalmic gel 0.15%

01.01.02 Gaviscon Advance 
  • Chewable TabletsSF (Contains 2.25 mmol of sodium, plus 1 mmol of potassium per tablet) 
  • SuspensionSF (Contains 2.3 mmol of sodium, plus 1 mmol of potassium per 5mL)  

Notes: 

  • Should not be prescribed in Primary Care or at Discharge.
  • Advise patient to purchase, unless prescription is for long-term regular use.
01.01.02 Gaviscon Infant 

Oral powderSF (Contains 0.92 mmol of sodium per dose) 

Important: Each half of the dual-sachet is identified as ‘one dose’. To avoid errors prescribe with directions in terms of "dose". 

08.01.05 Gefitinib Iressa®

Tablets 250mg

 

09.02.02.02 Gelatin Gelofusine®, Isoplex®

40g per 1ml (4%)

08.01.03 Gemcitabine Gemzar®

Injection, powder for reconstitution 200mg vial, 1g vial

07.01.01 Gemeprost 

Pessary 1mg

08.02.03 Gemtuzumab ozogamicin Mylotarg

5mg powder for concentrate for solution for infusion vials

 

05.01.04 Gentamicin 

Injection 20mg/2mL, 80mg/2mL

Note:

Use the Gentamicin Calculator. To avoid excessive dosage in obese patients, use ideal weight for height to calculate dose.

11.03.01 Gentamicin ophthalmic

Drops 0.3%

12.01.01 Gentamicin  

Ear drop 0.3%        

11.03.01 Gentamicin single use Minims® Gentamicin Sulphate

Preservative free eye drops 1.5%  

08.02.04 Glatiramer Acetate 

Copaxone® Injection, Glatiramer acetate 20mg/mL solution in Pre-filled
syringes
Copaxone® Injection, Glatiramer acetate 40mg/mL solution in Pre-filled
syringes

 

06.01.02.01 Glibenclamide 

5mg tablets

06.01.02.01 Gliclazide 

Tablets 80mg

06.01.02.01 Glimepiride 

Tablets 1mg, 2mg, 3mg, 4mg

06.01.04 Glucagon GlucaGen® HypoKit

Injection 1mg vial

06.01.04 GlucoGel® 
06.01.01.03 GlucoRx Carepoint 
09.02.02.01 Glucose Infusion 
  • 5% infusion, 500ml, 1 litre bags
  • 10% infusion, 500ml and 1 litre bags
  • 20% infusion, 100ml and 500ml bags
09.03 Glucose Oral 30% 

Glucose 30% Oral Solution

06.01.06 Glucose test strips 

See primary care guidelines for cost effective options

 

****Note to be added*****

01.06.02 Glycerol (Glycerin) 

Suppositories 1g, 2g, 4g  

01.07.04 Glyceryl Trinitrate Rectogesic®

Rectal ointment 0.4% (For 6 weeks up to a maximum of 8 weeks) 

02.06.01 Glyceryl Trinitrate 

Patches 5mg/24 hours, 10mg/24hours 

02.06.01 Glyceryl Trinitrate 
  • Tablets, sublingual 300 micgrograms, 500 micrograms, 600 micrograms
  • Spray 400 micrograms
02.06.01 Glyceryl Trinitrate 
  • Buccal modified release tablets 2mg, 3mg, 5mg (Hospital only)
  • Injection 5mg in 5ml, 50mg in 10ml, 25mg in 5mL (Hospital only)
02.06.01 Glyceryl Trinitrate 

Ointment 2%

18 Glyceryl Trinitrate 
  • Tablets, sublingual 300 micgrograms, 500 micrograms, 600 micrograms
  • Spray 400 micrograms
  • Patches 5mg/24 hours, 10mg/24hours
  • Ointment 2%
  • Buccal modified release tablets 2mg, 3mg, 5mg (Hospital only)
  • Injection 5mg in 5ml,50mg in 10ml, 25mg in 5mL (Hospital only)
07.04.04 Glycine 1.5% irrigation 

Glycine 1.5% irrigation

03.01.02 Glycopyrronium Seebri breezhaler®

Inhalation powder, hard capsule, (for use with Seebri Breezhaler® device), 50 micrograms.

DPI - Dry Powder Inhaler

15.01.03 Glycopyrronium Bromide  

 

  • 200 micrograms in 1mL amp
  • 600 micrograms in 3ml amp
03.01.04 Glycopyrronium/ indacaterol inhaler 

Please follow COPD Inhaler Device Pathway in the appendix to help maintain device consistency and follow associated pathway in a step wise approach.

Ultibro Breezhaler®

110mcg indacaterol/50mcg glcopyrronium

Hard capsule (inhalation powder) (DPI - Dry powder inhaler)

01.05.03 Golimumab Simponi®

Injection 50mg pre-filled pen or pre-filled syringe; 100mg pre-filled pen

10.01.03 Golimumab Simponi®

Simponi® 50mg in 0.5mL solution in pre-filled pen, 100mg in1mL solution in pre-filled pen

06.05.01 Gonadorelin HRF®

(Gonadotrophin-releasing hormone; GnRH; LH-RH)

Injection 100 microgram vial with diluent

 

For assessment of pituitary function

06.07.02 Goserelin 

Zoladex Implant 3.6mg every 28 days

03.04.02 Grass pollen extract Grazax®

Grazax allergy vaccine

  • Sublingual tablets for severe grass pollen allergy
  • Considered a LOW PRIORITY treatment due to lack of evidence of incremental clinical and cost effeectiveness when compared to existing therapies.

 

04.04 Guanfacine Intuniv®

 Tablets prolonged-release, 1mg, 2mg, 3mg, 4mg 

13.05.03 Guselkumab Tremfya®

100mg/1mL solution for injection in pre-filled syringes   

09.08.02 Haem Arginate Normosang®

Normosang® solution for infusion 25mg/ml

Note:

  • Many drugs can precipitate porphyria crisis. The BNF contains some guidance but please refer to Haematologists or the Medicines Information Centre at Milton Keynes Hospital for advice on prescribing for patients with acute porphyria.
  • Haemarginate (Normosang®) is kept in the Pharmacy Emergency Cupboard fridge for the treatment of acute porphyric crisis under the supervision of a Consultant Haematologist.
14.04 Haemophilus influenzae type B Combined Vaccine Menitorix®

Inj conjugate vaccine containing: Haemophilus influenzae type B vaccine, meningococcal group C (Hib/MenC)

02.11 Haemostatic gelatin sponge 

Film 200 x 70 x 0.5mm 

04.02.01 Haloperidol 
  • Capsules 500 micrograms
  • Tablets 1.5mg, 5mg, 10mg, 20mg
  • Oral liquid - Sugar free 2mg in 1mL
  • Injection 5mg/1mL 
04.02.02 Haloperidol Decanoate Haldol Decanoate®

Diluent = Sesame oil

Injection 100mg/mL  

02.08.01 Heparin (flushes) 
  • 10 units/mL; 5mL amp for IV Flush 
  • 100 units/mL; 2mL amp for IV Flush

Notes:

  • Cannulae intended to be in place for less than 48 hours should be flushed with Sodium Chloride 0.9% solution.
  • Heparin flush solution should be reserved for cannulae to be in place for longer than 48 hours. 
02.08.01 Heparin sodium 
  • 1000 units/mL; 1mL amp, 5mL amp, 5mL vial, 10mL amp, 20mL amp 
  • 5000 units/mL; 1mL amp, 5mL amp, 5mL vial 
  • 25,000 units/mL; 0.2mL amp, 1mL amp, 5mL vial
14.04 Hepatitis A vaccine 

Injection (Avaxim®, Havrix® monodose, Epaxal®, Vaqta®, Havrix® Junior Monodose)      

14.04 Hepatitis A vaccine with Hepatitis B vaccine  Twinrix®

Inj (Ambirix®, Twinrix® Adult, Twinrix® Paed)

14.04 Hepatitis A vaccine with Typhoid vaccine Viatim®

Inj (Hepatyrix®, ViATIM®)

Note:

Hepatitis A and typhoid vaccine has been included for instances where both vaccines are required and it is not practical to administer both vaccines separately.

Licensed for use as a booster even though hepatitis A and typhoid vaccines have different booster requirements

14.05.02 Hepatitis B immunoglobulin HBIG
  • 200 international units injection (for infant use)
  • 500 international units injection (for adults) 

Notes:

  • Pharmacy do not stock this product
  • Supplies are available from MKUH Blood Bank section within Pathology (Ext 85776)
14.04 Hepatitis B vaccine Engerix B®

20 micrograms per ml

 

  • Engerix B® 20 micrograms per ml
  • HBvaxPRO® 10 micrograms per ml
  • HBvaxPRO® 40 micrograms per ml
  • Fendrix® 40 micrograms per ml       

Notes:

  • Fendrix® is for active immunisation against hepatitis B virus infection for patients (15 years of age and older) with renal insufficiency (including pre-haemodialysis and haemodialysis patients).
16.01 Holoclar 

79,000 - 316,000 cells/cm2 living tissue equivalent  

14.04 Human papilloma virus vaccine Gardasil®

 0.5ml prefilled syringe

14.04 Human papilloma virus vaccine Cervarix®

 0.5ml prefilled syringe

07.02.01 Hyalofemme® vaginal moisturiser 

This product is double red and should not be prescribed. Suggest self-care / OTC purchase.

10.01 Hyaluronic acid Hyalgan®

Injection

10.03.01 Hyaluronidase 

Hyaluronidase 1500 units powder for solutin for injection ampoules

This is for enhanced permeation of sc or im injection.

This is NOT the intra-articular preparation.

02.05.01 Hydralazine 
  • Tablets 25mg, 50mg
  • Injection 20mg ampoule

Note: Hydralazine may be used in combination with long acting nitrates in moderate to severe chronic congestive cardiac failure when an ACE inhibitor is contra-indicated or not tolerated.

01.05.02 Hydrocortisone Colifoam®

Foam enema 10%

Notes:

  • Steroid foam enema of choice
  • £9.33 for a 14-dose container with one applicator
06.03.02 Hydrocortisone 

Tablets 10mg, 20mg

06.03.02 Hydrocortisone 

Injection (as sodium succinate) 100mg vial

12.03.01 Hydrocortisone Corlan®

Buccal tablets 2.5mg      

13.04 Hydrocortisone 
  • Ointment: 0.5%, 1%, 2.5%
  • Cream:  0.5%, 1%, 2.5%

Notes:

  • Hydrocortisone ointment and cream (1% or combination) is available over the counter for the treatment of allergic contact dermatitis, irritant dermatitis, insect bite reactions and mild to moderate eczema.
  • It cannot be sold for application to eyes/face, anogenital region, for use in pregnancy or children under 10 years and on broken or infected skin and has a license for a maximum of one week’s duration.
10.01.02.02 Hydrocortisone acetate Hydrocortistab®

Injection 25mg in 1ml

13.04 Hydrocortisone 1% with Clotrimazole 1% Canesten HC®

Cream, Hydrocortisone 1%, clotrimazole 1%

13.04 Hydrocortisone 1% with Miconazole 2% Daktacort®

Cream, Hydrocortisone 1%, miconazole nitrate 2%

12.01.01 Hydrocortisone with Antibacterials Otosporin®

Ear drops containing hydrocortisone 1%, Neomycin 3400u, Polymyxin B 10,000u/mL,  10mL 

13.11.06 Hydrogen Peroxide Solution BP 

Hydrogen peroxide is an oxidising agent 

Prescribing and dispensing information

With topical use

The BP directs that when hydrogen peroxide is prescribed, hydrogen peroxide solution 6% (20 vols) should be dispensed.

Strong solutions of hydrogen peroxide which contain 27% (90 vols) and 30% (100 vols) are only for the preparation of weaker solutions.

With oral (topical) use

When prepared extemporaneously, the BP states Hydrogen Peroxide Mouthwash, BP consists of hydrogen peroxide 6% solution (= approx. 20 volume) BP. 

Medicinal Forms

  • Solution 3% BP (10 Vols)
  • Solution 6% BP (20 Vols)
  • Solution 30% (100Vols) – Bleach – used only to prepare weaker solutions
  • Cream, Crystacide® 1%
13.02.01 Hydromol® 

Ointment

09.01.02 Hydroxocobalamin 

Injection 1mg/mL 

08.01.05 Hydroxycarbamide 

Capsule 500mg

Note:
To be prescribed generically for all indications

10.01.03 Hydroxychloroquine 

Tablets 200mg

13.05.03 Hydroxychloroquine 

Tablets 200mg  

11.08.01 Hydroxypropyl Guar Systane®
  • Propylene glycol 0.3%, polyethylene glycol 400 0.4% 
  • Preservative-free single use eye drops 

 

Note:

  • For artificial eyes
  • Multidose bottle may be used for up to six months after opening
  • In contact lens wearers, Systane® should be applied before inserting lenses and after removal to extend comfortable wearing times
03.04.01 Hydroxyzine 

Hydroxyzine hydrochloride

  • Tablets 10mg, 25mg

Note:

  • Hydroxyzine is favoured by the dermatologists for its anti-itch and sedating effects.
10.01 Hylan G-F 20 Synvisc®

Injection

01.02 Hyoscine butylbromide 
  • Tablets 10mg
  • Injection 20mg in 1mL (Hospital or Palliative Care Specialist Use Only)

Notes:

  • Hyoscine butylbromide may be useful in gastro-intestinal disorders characterised by smooth muscle spasm and in terminal care, but its anticholinergic side effects limit its use.
04.06 Hyoscine Hydrobromide 
  • Chewable tablets 150 micrograms, 300 micrograms
  • Patch 1mg per 72 hrs
  • Injection 400 micrograms in 1mL 
15.01.03 Hyoscine Hydrobromide  
  • 400 micrograms in 1ml amps
  • 600 micrograms in 1ml amps
11.08.01 Hypromellose 

Hypromellose

  • Eye drops 0.3%
  • Evolve® Hypromellose (preservative-free)

Notes:

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term regular use
08.01.05 Ibrutinib Imbruvica®

Imbruvica® Capsules 140mg

 

 

10.01.01 Ibuprofen 
  • Ibuprofen Tablets 200mg, 400mg, 600mg
  • Suspension SF 100mg in 5ml

Notes:

  • Should not be prescribed in Primary Care or at Discharge.
  • Advise patient to purchase, unless prescription is for long-term regular use.
  • Treatment should be reviewed after two weeks and stopped if not effective.
10.03.02 Ibuprofen gel 

Ibuprofen gel containing 5%

Should not be prescribed for self-limiting injuries. Patient to be advised to purchase over the counter.

08.01.02 Idarubicin Zavedos®

Capsules 5mg, 10mg

Injection, powder for reconstitution 5mg vial, 10mg vial

02.08 Idarucizumab Praxbind®

Injection 2.5g/50mL

Specific reversal agent for Pradaxa® Dabigatran etexilate

08.01.05 Idelalisib Zydelig®

Zydelig® Tablet film-coated 100mg, 150mg

08.01.01 Ifosfamide Mitoxana®

Injection 1g vial, 2g vial

02.05.01 Iloprost 

Injection 50 micrograms in 0.5mL

Information sheet for administration of Iloprost in Raynaud's/Scleroderma (ONLY)

 

08.01.05 Imatinib 

Glivec® Tablets film-coated 100mg, 400mg

 

05.01.02.02 Imipenem with Cilastatin 

Injection 500mg

04.03.01 Imipramine 

Tablets 10mg, 25mg

04.07.03 Imipramine 

Tablet 10mg, 25mg

13.07 Imiquimod Aldara®

Notes: Indications include     

  • Warts – external genital and perianal
  • Superficial basal cell carcinoma
  • Actinic keratosis 

 

02.02.01 Indapamide 

Tablets 2.5mg

05.03.01 Indinavir Crixivan®

Capsules 200mg, 400mg

07.01.01.01 Indometacin Indocid PDA®

Injection 1mg vial

10.01.01 Indometacin 
  • Capsules 25mg, 50mg
  • Suppositories 100mg
13.11.01 Industrial Methylated Spirit BP 

Solution 70% 

01.05.03 Infliximab Inflectra®

1st line Biosimilar agent

Intravenous infusion, powder for reconstitution, 100mg vial  

Specify brand when prescribing.

Notes:

  • First line brand for all licensed indications as this is the most cost-effective option.
  • If patient has a flare of the condition for which the Inflectra is being treated whilst on this medication, the patient should be switched to Remicade® and remain on this instead.
01.05.03 Infliximab Remsima®

2nd line Biosimilar agent

Intravenous infusion, powder for reconstitution, 100mg vial  

Specify brand when prescribing.

Not preferred, as a more cost-effective option/brand (Inflectra®) is available.

01.05.03 Infliximab Remicade®

(Original biologic)

Intravenous infusion, powder for reconstitution, 100mg vial  

Specify brand when prescribing.

10.01.03 Infliximab 

100mg vial powder for reconstition

13.05.03 Infliximab Remicade®

Injection 100mg vial   

14.04 Influenza vaccine  

0.5ml pre-filled syringe       

Notes: 

08.01.05 Inotuzumab Ozogamicin  Besponsa®

Mylotarg® 5mg powder for concentrate for solution for infusion vials

 

06.01.01.01 Insulin Actrapid®

100 units/ml

06.01.01.01 Insulin Humulin® S

100 units /ml

06.01.01.01 Insulin Insuman® Rapid

100 units/ml

06.01.01.01 Insulin Aspart  NovoRapid®

100 units/ml

06.01.01.01 Insulin aspart Fiasp®

100 units/ml

06.01.01.01 Insulin bovine Hypurin® Bovine Neutral

100 units /ml

06.01.01.02 Insulin degludec Tresiba®

100 units/ml

06.01.01.02 Insulin degludec Tresiba®

200 units/ml

06.01.01.02 Insulin Detemir Levemir®

100 Units/ml

06.01.01.02 Insulin Glargine Lantus®

100 units /ml

06.01.01.02 Insulin Glargine 300 units/ml Toujeo®

300 units /ml

06.01.01.02 Insulin Glargine biosimilar 

100 units/ml

06.01.01.02 Insulin Glargine biosimilar 

100 units/ml

06.01.01.01 Insulin Glulisine Apidra®

100 units/ml

06.01.01.01 Insulin Lispro 100 units/ml Humalog®

100 units/ml

06.01.01.01 Insulin Lispro 200 units/ml Humalog®

200 units/ml

06.01.01.01 Insulin porcine  Hypurin® Porcine Neutral

100 units/ml

06.01.01.02 Insulin Zinc suspension Hypurin®Bovine Lente

100 units/ml

08.02.04 Interferon Alfa-2a Roferon-A®

Interferon Alfa-2a (rbe), Roferon-A®
Injection, 3 million-unit in 0.5mL pre-filled syringe
Injection, 3 million-unit in 1mL vial
Injection, 4.5 million-unit in 0.5mL pre-filled syringe
Injection, 4.5 million-unit in 1mL vial
Injection, 6 million-unit in 0.5mL pre-filled syringe
Injection, 9 million-unit in 0.5mL pre-filled syringe

 

08.02.04 Interferon Beta-1a 

Avonex® Injection, 30mcg (6 million-unit) powder and solvent for
solution (BIO-SET)
Avonex® Injection, 30mcg/0.5mL (6 million-unit) solution in Pre-filled syringe
Avonex® Injection, 30mcg/0.5mL (6 million-unit) solution in Pre-filled pen

 

 

08.02.04 Interferon Beta-1a Rebif®

Rebif® Injection, 22mcg (6 million-unit) prefilled syringe or pen
Rebif® Injection, 44mcg (12 million-unit) prefilled syringe or pen
Rebif® Injection, 44mcg (12 million-units/mL) 1.5mL (66mcg, 18 million-unit) cartridge
Rebif® Injection, 88mcg (24 million-units/mL) 1.5mL (132mcg, 36 million-unit) cartridge

08.02.04 Interferon Beta-1b 

Betaferon® Injection, 300mcg (9.6 million-unit) powder for reconstitution, vial with diluent



08.02.04 Interferon beta-1b Extavia®

Extavia® Injection, 300mcg (9.6 million-unit), powder for reconstitution, vial
with diluent

09.03 Intralipid® 10% 

500mL

09.03 Intralipid® 20% 

500mL

06.02.02 Iodine and Iodide 

Aqueous iodine  oral solution 30ml, 500ml

 

 

08.01.05 Ipilimumab Yervoy®

Yervoy® Concentrate for Intravenous Infusion 5mg/mL: 10mL, 40mL vial

 

03.01.02 Ipratropium bromide 
  • Metered Dose Inhaler (MDI) 20 micrograms/dose
  • Nebuliser solution 250 micrograms in 1mL, 500 micrograms in 2mL

 

Notes:

  • Patients must be instructed in the correct administration of ipratropium nebuliser solution.
  • Care must be taken not to allow the solution or mist to enter the eyes.
  • It is recommended that the nebulised solution be administered via a mouthpiece. If this is not available and a nebuliser mask is used, it must fit properly.
  • Patients who may be predisposed to glaucoma should be warned specifically to protect their eyes. 
12.02.02 Ipratropium Bromide Rinatec®

 Nasal spray 0.03%      

Notes:

 Ipratropium may be useful to treat non-allergic watery rhinorrhoea. It does not act directly to reduce blood flow to the nose but reduces watery secretions

02.05.05.02 Irbesartan 

Tablets 75mg, 150mg, 300mg

09.01.01.02 Iron Dextran CosmoFer®

Injection 50mg/mL

09.01.01.02 Iron Sucrose Venofer®

Injection 20mg/ml

15.01.02 Isoflurane 

 250mL

05.01.09 Isoniazid 
  • Tablets 100mg
  • Injection 50mg/2ml
  • Elixir 50mgin 5ml, unlicensed; prescribers are to restrict prescribing to this strength
06.01.01.02 Isophane Insulin Hypurin® Porcine Isophane

100 units/ml

06.01.01.02 Isophane Insulin Insulatard®

100 units/ml

06.01.01.02 Isophane Insulin Humulin® I

100 units/ml

06.01.01.02 Isophane Insulin Insuman® Basal

100 units/ml

02.06.01 Isosorbide Dinitrate 
  • Tablets 10mg, 20mg
  • Tablets modified release, 20mg, 40mg
  • Injection 0.1% = 1mg/mL (10mL amp) 

Note: Nitrate free periods can be achieved by prescribing ordinary release nitrates twice a day, first thing in the morning and mid afternoon.

02.06.01 Isosorbide Mononitrate 
  • Tablets 10mg, 20mg, 40mg
  • Tablets modified release 60mg (tablets can be halved) 
13.06.02 Isotretinoin 
  • Capsules 5mg, 20mg 

Notes:

13.06.01 Isotretinoin Gel 0.05% Isotrex® gel
13.06.01 Isotretinoin with antibacterial Isotrexin®
  • Gel, isotretinoin 0.05%, erythromycin 2%

 

01.06.01 Ispaghula Husk 

Sachets 3.5g

05.02 Itraconazole 
  • Capsules 100mg (Amber 2)
  • Oral suspension 10mg per 1ml sugar free (Hospital only, Red)

Notes:

  • Itraconazole is for the treatment of Aspergillosis only.
  • Itraconazole has been associated with liver damage, and should not be given to patients with liver disease.
  • CSM advise - Heart failure - Following rare reports of heart failure, the CSM has advised caution when prescribing itraconazole to patients at high risk of heart failure. Those at risk include: Patients receiving high doses and longer treatment courses, older patients and those with cardiac disease, patients receiving treatment with negative inotropic drugs, e.g. Calcium Channel Blockers.
02.06.03 Ivabradine 

Tablets 5mg, 7.5mg 

Notes:

  • For Consultant initiation only.
  • Treatment of coronary artery disease: Ivabradine is to be used only in patients with chronic stable angina pectoris with normal sinus rhythm, who have a contraindication or intolerance for beta-blockers. This intolerance must be shown before Ivabradine is considered.
  • Treatment of chronic heart failure: Use as per NICE TA267 Ivabradine for the treatment of chronic heart failure (November 2012).
  • Treatment with ivabradine should be started by a specialist. But after that either a GP with a special interest in heart failure or a heart failure specialist nurse can adjust the dose and monitor the patient's condition.
  • Unlicensed Use - For Hospital Cardiology Specialist Precribing Only: As pre-treatment for optimising heart rate prior to CT coronary angiography (unlicensed indication).
13.06 Ivermectin cream Soolantra®

One gram of cream contains 10 mg of ivermectin

08.01.05 Ixazomib Ninlaro®

Ninlaro® Capsules 2.3mg, 3mg, 4mg

 

13.05.02 Ixekizumab Taltz®

 Solution for injection 80mg/1mL in pre-filled syringe / in pre-filled pen

19 Jobst Comprifore Bandages 

#1 Absorbent Padding Latex Free

#2 Light Forming Latex Free

#3 Light Compression Latex Free 10cm x 8.7cm

#4 Flex ible Cohesive Latex Free 10cmx 2.5cm

Jobst Comprifore Bandages web site

19 K- Lite 

10cm x 5.25m

19.01 K- Lite Long 
09.03 Kabiven 11g N (Manipulated) 2073mL 

Central PN

09.03 Kabiven 14g N (Manipulated) 2586mL 

Central PN

09.03 Kabiven 7g N (Manipulated) 1940mL 

Peripheral or Central PN

19 Kaltostat®  Alginate Dressing

7.5cm x 12cm

Kaltostat web site

10.03.02 Kaolin Poultice 
15.01.01 Ketamine injection 
  • 200mg in 20mL vial
  • 500mg in 10mL vial
  • 1g in 10mL vial

Note:

  • Ketamine may be used as an analgesic in low doses. 
11.08.02 Ketorolac Acular®

Eye drops 0.5% (Contains: benzalkonium chloride, disodium edetate)

15.01.04.02 Ketorolac Toradol®
  • 10mg in 1mL amp
  • 30mg in 1mL amp

Note: Licensed for use in short-term management of moderate to severe post operative pain only.

02.04 Labetalol hydrochloride 
  • Tablets 100mg, 200mg, 400mg
  • Injection 5mg/mL (20-mL amp) - Hospital only

 Note: Labetalol may be used for the treatment of hypertension in pregnancy.

01.06.04 Lactulose 

Solution

Notes: 

  • Lactulose takes up to 48 hours to work but is often inappropriately used “when required”.
  • It is unpleasant to take and compliance may be a problem.
  • Its main clinical benefit is in the management of hepatic encephalopathy.
  • Should not be routinely prescribed for infrequent constipation in Primary Care or at Discharge.
  • Advise patient to purchase, unless prescription is for long-term regular use.
05.03.01 Lamivudine Epivir®
  • Tablets film-coated, 150mg, 300mg
  • Oral Solution 10mg/mL (240mL with oral syringe) 
05.03.01 Lamivudine Zeffix®

Tablets 100mg

04.02.03 Lamotrigine 
  • Tablets 25mg, 50mg, 100mg, 200mg
  • Dispersible tablets 5mg, 25mg, 100mg  

Note: 

  • The CSM has advised prescribers to be alert for symptoms and signs suggestive of bone-marrow failure such as anaemia, bruising or infection.
04.08.01 Lamotrigine 
  • Tablets 25mg, 50mg, 100mg, 200mg
  • Dispersible tablets 5mg, 25mg, 100mg  

Note: 

  • The CSM has advised prescribers to be alert for symptoms and signs suggestive of bone-marrow failure such as anaemia, bruising or infection.
16.01 Lanadelumab 

Solution for injection, 300mg/2ml vial

01.03.05 Lansoprazole 
  • Capsules 15mg, 30mg
  • Dispersible tablets 15mg, 30mg 
09.05.02.02 Lanthanum Fosrenol ®
  • Fosrenol® chewable tablets lanthanum carbonate hydrate 500mg
  • Fosrenol® chewable tablets lanthanum carbonate hydrate 750mg
  • Fosrenol® chewable tablets lanthanum carbonate hydrate 1g
  • Fosrenol® powder lanthanum carbonate hydrate 750mg
  • Fosrenol® powder lanthanum carbonate hydrate 1g

Note:

  • For use by the Renal Team only.
  • Renagel and Lanthanum are available for third line management of hyperphosphataemia in dialysis patients with serum phosphate levels that are not controlled, or where aluminium and calcium salts are inappropriate.
08.01.05 Lapatinib Tyverb®

Tablet 250mg

 

11.06 Latanoprost Xalatan®

Xalatan® Eye drops 50 micrograms/mL

Latanoprost (Monopost®) Amber 1

  • Single-use eye drops 50 micrograms/mL Note: Consultant initiation only

 

 

11.06 Latanoprost with Timolol 

Eye drops latanoprost 50 micrograms, timolol (as maleate) 5 mg/mL

10.01.03 Leflunomide 

Tablets 10mg, 20mg

08.02.04 Lenalidomide 

Lenalidomide Capsules 5mg, 10mg, 15mg, 25mg

09.01.06 Lenograstim Granocyte®
  • Pre-filled syringe 13.4 million units (105 micrograms)
  • Pre-filled syringe 33.6 million units (263 micrograms)  
08.01.05 Lenvatinib 

Kisplyx® Capsules 4mg, 10mg
Lenvima® Capsules 4mg, 10mg

 

05.03.02.02 Letermovir Prevymis®

240mg film-coated tablets

08.03.04.01 Letrozole 

Tablets 2.5mg

 

06.07.02 Leuprorelin 

Prostap® SR DCS Injection, dual-chamber prefilled syringe containing powder for reconstitution, by subcutaneous or by intramuscular
injection, 3.75mg every month


Prostap® 3 DCS Injection, dual-chamber prefilled syringe containing powder
for reconstitution, by subcutaneous injection, 11.25mg every 3 months

04.08.01 Levetiracetam 
  • Tablets 250mg, 500mg, 750mg, 1g
  • Oral solution 100mg/mL 
  • Intravenous infusion 100mg/mL (Hosp only)
11.06 Levobunolol Betagan
  • Eye drops, levobunolol hydrochloride 0.5%, polyvinyl alcohol (Liquifilm®) 1.4%
  • Single use eye drops, levobunolol hydrochloride 0.5%, polyvinyl alcohol (Liquifilm®) 1.4%

 

Note:  Consultant initiation only

09.08.01 Levocarnitine Carnitor®
  • Oral liquid 100mg per 1ml = 1g/10ml, 10% solution
  • Oral liquid 300mg per 1ml = 1.5g/5ml, 30% Paediatric solution
  • Injection 200mg per 1ml = 1g in 5ml soultion
05.01.12 Levofloxacin 
  • Tablets 250mg, 500mg
  • Intravenous Infusion, 500mg/100mL infusion
  • Solution for infusion, 500mg/100mL vials
  • Solution for infusion, 500mg/100mL bottles

Notes:

Important Safety Information:

13.03 Levomenthol  Arjun®
04.06 Levomepromazine 
  • Tablets 25mg
  • Injection 25mg/mL  

 

Note:

  • For Palliative Care use
07.03.05 Levonorgestrel 1.5mg 

Levonorgestrel 1.5mg tablet

First choice oral emergency contraception for patients presenting within 72hrs of unprotected sexual intercourse.

Prescribe generically.

Available free of charge to under 25s via PGD through some pharmacies in Milton keynes

Do not prescibe as the OTC preparation (Levonelle One Step) as it is more than twice the cost of the POM product.

07.03.02.03 Levonorgestrel 13.5mg  Jaydess®

Levonorgestrel 13.5mg as Jaydess®

Prescribe by brand name.

Offers contraception for up to 3 years.

07.03.02.03 Levonorgestrel 19.5mg Kyleena®

Levonorgestrel 19.5mg as Kyleena®

Prescribe by brand name.

Offers contraception for up to 5 years.

07.03.02.03 Levonorgestrel 52mg Mirena®

Levonorgestrel 52mg as Mirena®

Prescribe by brand name.

Offers contraception for up to 5 years.

06.02.01 Levothyroxine 

Tablets 25 micrograms, 50 micrograms, 100 micrograms
Oral solution 25 micrograms/5ml, 50 micrograms/5ml, 100 micrograms/5ml

15.02 Lidocaine  

  Plaster 5%  700mg/plaster

1) Licensed use: for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN) in adults. For specialist pain clinic team initiation and stabilisation. Hospital to prescribe one months supply before asking GPs to continue to prescribe

2) Unlicensed use: for treatment of neuropathic pain in selected palliative patients with mesothelioma or chest wall disease. For specialist initiation and stabilisation. Hospital to prescribe one months supply before asking GPs to continue to prescribe

3) Unlicensed use: Patients with fractured rib. For specialist prescribing. Hospital to prescribe one months supply. GPs should not be asked to continue to prescribe.

Lidocaine Plasters Commissioning Statement

 

NOTE: This statement does not apply to patients who have been treated in line with

 

Apart from the exception above:

Prescribers should not initiate lidocaine plasters for any new patient.

Lidocaine plasters should be discontinued from primary care prescribing (deprescribed), with support from specialist services if necessary.

If, in exceptional circumstances, there is a clinical need for lidocaine plasters to be

prescribed in primary care, this should be undertaken in a cooperation agreement with a

multi-disciplinary team and/or other healthcare professional.

11.07 Lidocaine 4% with Fluorescein 0.25% Minims®

Minims® Eye drops, single use, preservative-free

Notes: 

  • Ophthalmic Consultant use only
  • Local anaesthetic and staining
02.03.02 Lidocaine hydrochloride 
  • Injection 1% containing Lidocaine 10mg per 1mL (2-mL amp, 5-mL amp, 10-mL amp, 20-mL amp)
  • Injection 2% containing Lidocaine 20mg per 1mL (2-mL amp, 5-mL amp, 10-mL amp, 20-mL amp)
  • Infusion 0.2% (2mg per 1mL in 500mL of 5% Glucose)
  • Injection - Minijet 2% containing Lidocaine 20mg per 1mL (5-mL disposable syringe) 
04.07.03 Lidocaine plaster 

Note: Classed as a "Low Value Medicine"

Versatis® Plaster 5%, 700mg/plaster

1) Licensed use: For the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN) in adults. For specialist pain clinic team initiation and stabilisation. Hospital to prescribe one month's supply before asking GPs to continue to prescribe.

2) Unlicensed use: For the treatment of neuropathic pain in selected palliative patients with mesothelioma or chest wall disease. For specialist initiation and stabilisation. Hospital to prescribe one month's supply before asking GPs to continue to prescribe.

3) Unlicensed use: Patients with fractured rib. For specialist prescribing. Hospital to prescribe one month's supply. GPs should not be asked to continue to prescribe.

 

Please refer to the guidance which details the requirements for the transfer of prescribing responsibilities from secondary to primary care for patients.

 

Lidocaine Plasters Commissioning Statement

NOTE: This statement does not apply to patients who have been treated in line with NICE CG173 Neuropathic pain in adults: pharmacological management in non-specialist settings but are still experiencing neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia).

 

Apart from the exception above:

If, in exceptional circumstances, there is a clinical need for lidocaine plasters to be prescribed in primary care, this should be undertaken in a cooperation agreement with a multi-disciplinary team and/or other healthcare professional.

Patient Information Leaflet can be found at: https://www.formularymk.nhs.uk/includes/documents/Patient-information-Changes-to-lidocaine-plaster-prescribing.pdf

 

01.06.07 Linaclotide 

Capsules 290 micrograms

Notes:

Consider linaclotide for people with IBS only if:

  • optimal or maximum tolerated doses of previous laxatives from different classes have not helped and
  • they have had constipation for at least 12 months
06.01.02.03 Linagliptin Trajenta®

Tablets 5mg

06.01.02.03 Linagliptin/ metformin Jentadueto®

Jentadueto® Tablets 2.5mg/850mg, 2.5mg/1g

05.01.07 Linezolid 
  • Tablets 600mg
  • Intravenous Infusion, 600mg/300mL infusion bags

Note:  It is only available from a hospital pharmacy following advice from microbiology.

06.02.01 Liothyronine (IV) 

Injection 20 micrograms

06.02.01 Liothyronine (oral) 

Tablets 20 microgram

For existing patients only

Liothyronine (oral) is not recommended for prescribing in Milton Keynes and
is therefore classified Double Red for all new patients.
Liothyronine (oral) is not supported by local NHS endocrinologists and it is not
included in the recommendations for the treatment of hypothyroidism from the
Royal College of Physicians.
The British Thyroid Association recommends levothyroxine as the standard
treatment for hypothyroidism. Treatment with combination L-T3 plus L-T4
should only be considered in exceptional cases and should be started and
supervised by accredited endocrinologists.
The Milton Keynes Prescribing Advisory Group (MKPAG) does not recommend
liothyronine (T3) as a treatment option for resistant depression in adults.
The only UK licensed liothyronine tablet is available as a 20mcg strength. Other
strengths are available from special's manufacturers but are not licensed in the
UK and should not be routinely prescribed. Liothyronine currently costs
approximately £3000 per patient per year based on a 10 microgram twice daily
dose. The equivalent daily dose of levothyroxine is 100 micrograms and costs
the NHS approximately £20 per patient per year.
There are potential risks from liothyronine therapy (on the bone - osteoporosis

08.01.02 Liposomal Cytarabine-Daunorubicin Vyxeos®

Vyxeos® 44mg/100mg powder for concentrate for solution for infusion, vials

 

13.02.01 Liquid and White Soft Paraffin Ointment (50:50) 

Ointment

11.08.01 Liquid Paraffin  Hylo Night®

Hylo Night® (Previously VitA-POS®) eye ointment contains Retinol palmitate 250iu/g, liquid paraffin, wool fat

Notes:

  • Can be used at any stage of dry eye treatment
  • Not suitable with contact lenses.
  • Best suited for application before sleep.

Key product features that remain the same:

  • Preservative & phosphate free
  • 6 months sterility from time of opening
  • Allows for 300 individual applications

 

01.06.03 Liquid Paraffin BP 

Oral emulsion

06.01.02.03 Liraglutide Victoza®

Victoza® Injection 6mg/mL

04.04 Lisdexamfetamine Elvanse®

Elvanse® Capsules 30mg, 50mg, 70mg 

02.05.05.01 Lisinopril 

Tablets 2.5mg, 5mg, 10mg, 20mg 

04.02.03 Lithium Carbonate Priadel®

 Modified Release tablet 200mg, 400mg 

Lithium Shared Care Guideline 

04.02.03 Lithium Citrate 

Priadel® Sugar Free Liquid 520mg (equivalent to 5.5mmol Li+) in 5mL

Notes: 

  • Dose equivalence and conversion: Lithium citrate tetrahydrate 520mg is equivalent to lithium carbonate 204mg.
  • Priadel® should be preferred for all new patients.
  • It is not intended that patients stabilised on Camcolit® should be changed to Priadel®.
  • Please specify the brand when prescribing lithium to ensure that the patient receives the same preparation. Different brands of lithium are not equivalent.
06.01.02.03 Lixisenatide Lyxumia®

Lyxumia® Injection, 50micrograms/mL (10micrograms/dose prefilled pen),
100micrograms/mL (20 micrograms/dose prefilled pen.

Notes:
 
  • Prescribers should consider stopping Lixisenatide when HbA1c has not reduced by 1% and weight by 3% of initial body weight at 6 months  
04.03.01 Lofepramine 

Tablets 70mg

08.01.01 Lomustine 

CCNU® capsules 40mg

01.06.05 lookedMacrogols Moviprep®

Oral powder - Sugar free

01.04.02 Loperamide 
  • Capsules 2mg 
  • Oral Syrup Sugar-free 1mg/5mL 
  • Orodispersible Tablets 2mg (Hospital use only by stoma care team)

Notes

  • Should not be prescribed in Primary Care or at Discharge.
  • Advise patient to purchase, unless prescription is for long-term regular use.
05.03.01 Lopinavir and Ritonavir Kaletra®
  • Kaletra® Tablets film coated, 100mg/25mg, 200mg/50mg
  • Kaletra® Oral solution, (80mg + 20mg) per 1mL
  • Epivir® Oral solution, 10mg/mL (240mL with oral syringe)
03.04.01 Loratadine 

Loratadine

  • Tablets 10mg
  • Oral solution 5mg in 5mL

Notes:

Should not be prescribed in Primary Care or at Discharge.  Advise patient to purchase, unless prescription is for long-term regular use.

04.01.02 Lorazepam 

Tablets 1mg, 2.5mg

04.08.02 Lorazepam 
  •  Tablets 1mg, 2.5mg
  •  Intravenous injection 4mg in 1mL (Hospital only)

Note:

  • Pfizer, the sole licensed UK supplier of Ativan (lorazepam 4mg/ml injection), are experiencing supply issues and there may be limited supply and stock restrictions.
15.01.04.01 Lorazepam 
  • Tablet
  • Oral suspension
  • solution for injection
02.05.05.02 Losartan 

Tablets 12.5mg, 25mg, 50mg, 100mg 

11.04.01 Loteprednol Lotemax®

Eye drops: Loteprednol etabonate 0.5%

Notes:

  • (Apart from postoperative situation) for steroid responder patients requiring topical steroids
09.01.04 Lusutrombopag 

3mg tablets

08.03.04.03 Lutetium (177Lu) oxodotreotide Lutathera®

Injection for intravenous Infusion

 

05.01.03 Lymecycline 

Capsules 480mg

13.06.02 Lymecycline Tetralysal®300
  • capsules 408mg

Note:

  • A good first line antibiotic as compliance is good (it can be taken with food) and bacterial resistance is less than with first generation tetracyclines
01.01.01 Maalox Plus 
01.06.04 Macrogol oral powder 
  • Laxido® orange oral powder, sachets
  • Movicol® – Half sachets
  • Movicol® Paediatric plain sachets
01.06.04 Macrogol oral solution 

Movicol® liquid - This preparation is a liquid concentrate.

Dosage: 25ml (diluted in 100ml water) 1 to 3 times daily in divided doses, adjusted according to response.

Usual maximum duration: 2 weeks, repeated if required. For extended use, 1 or 2 doses daily.

Notes:

  • Laxido® or Movicol® preparations should be reserved only for patients where other treatments have been ineffective. 
  • Caution: may cause electrolyte disturbances.
  • There is currently insufficient evidence to support its routine use before well-established, less expensive drugs.
01.06.05 Macrogols Klean-Prep®

Oral powder - Sugar free

09.05.01.03 Magnesium Aspartate Magnaspartate®

Magnaspartate® Powder in Sachets containing magnesium (as aspartate dihydrate) 243mg (10mmol) per 6.5g peach/apricot flavoured powder in sachet for oral solution

09.05.01.03 Magnesium Glycerophosphate 

Neomag® Chewable Tablets containing 97mg (4mmol) magnesium per tablet

09.05.01.03 Magnesium Glycerophosphate 

Liquid containing 10 mmol in 10ml

07.01.03 Magnesium sulphate 

Off label use

 

For:

Prevention of seizures in pre-eclampsia
Treatment of seizures and prevention of seizure recurrence on eclampsia

09.05.01.03 Magnesium Sulphate 

Injection 50% (approximately 2 mmol magnesium per mL) 10mL amps

Note:

  • Magnesium deficiency is rare.
  • Magnesium sulfate may be used to treat pre-eclamptic arrhythmias. 
13.10.04 Malathion 0.5% Derbac-M®

Liquid, 0.5% malathion in aqueous basis

Notes: 

  • Should not be prescribed in Primary Care or at Discharge
  • Advise patient to purchase, unless prescription is for long-term regular use
  • Indications: Head lice, Crab lice, Scabies
  • DoseHead lice, rub 0.5% preparation into dry hair and scalp, allow to dry naturally, remove by washing after 12 hours (see also notes above); repeat application after 7 days
  • DoseCrab lice, apply 0.5% aqueous preparation over whole body, allow to dry naturally, wash off after 12 hours or overnight; repeat application after 7 days
02.02.05 Mannitol 
  • Intravenous Infusion 10% - 500mL in viaflo bag (PVC and latex free)
  • Intravenous Infusion 20% - 500mL in viaflex bag

Note: These are rarely used in heart failure as they may actually expand the blood volume. Mannitol is used in cerebral oedema. 

16.01 Mannitol 2.5% & Carob bean gum 0.2% 

Oral solution 500ml

Note: For use by Radiology for outlining the small bowel for MRI scans

03.07 Mannitol inhalation Bronchitol ®

Bronchitol® Inhalation powder, hard capsule (for use with disposable inhaler device), 40mg

05.03.01 Maraviroc Celsentri®

Tablets 150mg, 300mg

14.04 Measles, Mumps and Rubella Vaccine, Live (MMR) 

Injection (M-M-RvaxPro®, Priorix®)  

05.05.01 Mebendazole 
  • Tablets (chewable) 100mg
  • Oral Suspension 100mg/5mL

Note:  Should not be prescribed in Primary Care or at Discharge. Advise patient to purchase.

01.02 Mebeverine hydrochloride 

Tablets 135mg

19.01 Medi Derma-Pro Skin Protectant

Ointment 115g

19.01 Medi Derma-S Sachets

2g sachet

19.01 Medi Derma-S Pump Spray

Pump spray 30ml

19.01 Medi Derma-S Sterile Applicators 3ml
19.01 Medi Derma-S Barrier Cream

28g cream

19.01 Medi Derma-S  Sterile Applicators 1ml
08.03.02 Medroxyprogesterone Provera®

Tablets 100mg, 200mg, 400mg

06.04.01.02 Medroxyprogesterone Acetate 

Tablets 5mg, 10mg

 

 

06.04.01.02 Medroxyprogesterone Acetate 

Tablets 5mg, 10mg

 

 

07.03.02.02 Medroxyprogesterone acetate 104mg/0.65ml Sayana Press®

Medroxyprogesterone acetate 104mg/0.65ml pre-filled injector as Sayana Press®

Long acting reversible contraception

Suitable for self-administration by patient every 13 weeks

07.03.02.02 Medroxyprogesterone Acetate 150mg/ml Depo-Provera®

Medroxyprogesterone Acetate 150mg/ml as Depo-Provera®

Long acting reversible contraception

HCP administered every 12 weeks

10.01.01 Mefenamic Acid 
  • Capsule 250mg (cost effective choice)
  • Tablets 500mg

Notes:
a) Restricted to first line use only in patients that require a reduction in blood flow, e.g. patient with both menorrhagia and dysmenorrhea.
b) Restricted to second line use in patients intolerant to other NSAIDs.

08.03.02 Megestrol Megace®

Tablets 160mg

04.01.01 Melatonin Circadin®

Tablets, Modified release, 2mg

 Paediatric use

 

Melatonin must only be initiated by a paediatrician in children.

04.01.01 Melatonin Circadin®

Tablets, Modified release, 2mg

Adult Use  

Melatonin is approved for use in patients with Parkinsons Disease. The hospital will provide the initial 14 days' supply and ensure patient is responding to therapy before continuation of prescribing is transferred to the GP.

04.01.01 Melatonin Circadin®

Tablets, Modified release, 2mg

Adult use 

Melatonin is approved for new onset delirium whilst an inpatient. It must be initiated by a Consultant Neurologist – Hospital to provide the full course and no further supply should be required from the GP.

08.01.01 Melphalan 

Tablets 2mg

Injection 50mg vial

04.11 Memantine 
  • Tablets 10mg, 20mg, initiation pack
  • Oral solution pump pack 5mg per actuation (10mg per mL)
09.06.06 Menadiol Sodium Phosphate 

Tablets 10mg

Menadiol sodium phosphate is water-soluble and is included for use where patients have fat malabsorption syndromes.

14.04 Meningococcal group B Vaccine Bexsero®

Inj (Bexsero®) 

14.04 Meningococcal group C conjugate vaccine 

Inj (NeisVac-C®)   

Notes:

  • To be given as part of immunising individuals with asplenia, see current Green Book chapter 7
14.04 Meningococcal groups A, C, W135, and Y conjugate vaccine Menveo®or Nimenrix ®

Inj (Nimenrix®, Menveo®)

14.04 Meningococcal polysaccharide A, C, W135 and Y vaccine ACWY Vax®

Inj (Nimenrix®, Menveo®)

03.08 Menthol and Eucalyptus Inhalation BP 1980 

Eucalyptus with menthol

  • Inhalation, BP 1980

Notes:

Should not be prescribed in Primary Care or at Discharge. Advise patient to purchase.

03.04.02 Mepolizumab Nucala®

Nucala® Injection, 100mg powder for reconstitution

 

 

04.07.02 Meptazinol Meptid®
  • Meptid® Tablet 200mg
  • Meptid® Injection 100mg in 1mL (Hospital only) 
09.08.01 Mercaptamine Cystagon®

Tablets 50mg

01.05.03 Mercaptopurine 

Tablets 50mg

08.01.03 Mercaptopurine 

Tablets 50mg
Tablets 10mg U
Suspension 100mg in 5mL

Note:
Avoid concomitant use of mercaptopurine with allopurinol, unless supervised by
an appropriate specialist.

A2.02.01 Meritene® 

Meritene® Strength and Vitality powder milkshake and Meritene® Strength and vitality Chicken Soup powder soup are available to buy over the counter or online and are an option if patient does not meet ACBS Criteria.

05.01.02.02 Meropenem Meronem®

Injection 500mg, 1 gram

01.05.01 Mesalazine Octasa®

Modified release tablets 400mg, 800mg

Octasa is our preferred brand of mesalazine tablet; the 800mg tablets are large and relatively more expensive than the 400mg tablets; consider using 2 x 400mg when a dose of 800mg is required if appropriate.

01.05.01 Mesalazine Salofalk®

Foam enema 1g

01.05.01 Mesalazine Pentasa®

Modified release tablets 500mg, 1g

For new patients only after specialist recommendation for patients unable to take or have failed on Octasa.

01.05.01 Mesalazine Salofalk®

Gastro-resistant prolonged-release granules 500mg, 1g, 1.5g, 3g

Note: Only for patients who are unable to take tablets 

01.05.01 Mesalazine Salofalk®

Suppositories 500mg, 1g

Note: Mesalazine suppositories are a useful alternative to steroid enemas in maintenance therapy.

01.05.01 Mesalazine  Mezavant® XL

Tablets 1.2g

For those patients that Octasa is unsuitable where a once daily regimen is required for compliance purposes

08.01 Mesna 

Tablets 400mg, 600mg
Injection 400mg/4mL, 1g in 10mL

02.07.02 Metaraminol 

Injection 10mg in 1mL

(Available from 'special order' manufacturers or specialist importing companies)

06.01.02.02 Metformin 

Tablets 500mg, 850mg

Oral solution, 500mg in 5ml

Glucophage modified release tablets 500mg, 750mg, 1000mg

 

 

Metformin MR should only be used where the standard-release tablets have
been tried and are not tolerated due to GI problems, despite gradual dose
titration. Any new prescription of the MR preparation should be reviewed soon
after initiation and discontinued if not tolerated or ineffective.

16.01 Methacholine Chloride 

60 micrograms/ml, 125 micrograms/ml, 250 micrograms/ml, 500 micrograms/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml

20 Methacholine solutions various strengths Methylcholine, Acetyl-β-methylcholine
  • (Methylene blue)
  • Injection 1%, 10mL
  • Sterile solution 1%, 10mL
04.10.03 Methadone 

Oral solution, sugar free, 1mg/1mL

05.01.13 Methenamine Hippurate Hiprex®

Tablets 1g (Hiprex)

10.02.02 Methocarbamol Robaxin®

Should not be prescribed - limited clinical value

01.05.03 Methotrexate 

Tablets 2.5mg

Notes

Methotrexate dose is weekly.

To avoid errors it is recommended that:

  • The patient is carefully advised of the dose and frequency and the reason for taking methotrexate and any other prescribed medicine (e.g. folic acid). 
  • The prescription and the dispensing label clearly show the dose and frequency of administration.
  • The patient is warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising and mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort and dark urine), and respiratory adverse effects (e.g. shortness of breath). 
08.01.03 Methotrexate 

Red for malignant conditions

Tablets 2.5mg, 10mg

Injection 50mg in 2mL
Metoject® PEN solution for injection in pre-filled pen (all strengths)

Notes:
Guideline for oral methotrexate.

The 10mg tablets are reserved for Haematology and Oncology use only

In the treatment of non-cancer conditions (eg. rheumatology and
dermatology), methotrexate must be given once a week or once a month.

Staff that encounter methotrexate prescriptions must ensure the correct dosing
interval is given.

In Patients who experience mucosal or gastro-intestinal side effects with
methotrexate, folic acid 5mg each week may help reduce the frequency of such
side effects.

Methotrexate-induced mucositis or myelosuppression. Folinic acid (given as
calcium folinate) is used to counteract the folate-antagonist action of
methotrexate and so facilitate recovery from methotrexate-induced mucositis or
myelosuppression.

08.01.03 Methotrexate 

Amber SCG for non-malignant conditions

Tablets 2.5mg, 10mg

Injection 50mg in 2mL
Metoject® PEN solution for injection in pre-filled pen (all strengths)

Notes:
Guideline for oral methotrexate.

The 10mg tablets are reserved for Haematology and Oncology use only

In the treatment of non-cancer conditions (eg. rheumatology and
dermatology), methotrexate must be given once a week or once a month.

Staff that encounter methotrexate prescriptions must ensure the correct dosing
interval is given.

In Patients who experience mucosal or gastro-intestinal side effects with
methotrexate, folic acid 5mg each week may help reduce the frequency of such
side effects.

Methotrexate-induced mucositis or myelosuppression. Folinic acid (given as
calcium folinate) is used to counteract the folate-antagonist action of
methotrexate and so facilitate recovery from methotrexate-induced mucositis or
myelosuppression.

10.01.03 Methotrexate 

Tablets 2.5mg

Metoject Injection prefilled syringe 10mg, 15mg, 20mg, 25mg

1. CSM Warning – Methotrexate: In view of reports of blood dyscrasias (including
fatalities) and liver cirrhosis with low-dose methotrexate, the CSM has advised:
specific monitoring guidance (superseded by NPSA alerts and nGMS);
that patients should be advised to report all symptoms and signs suggestive of infection, especially sore throat.
2. Treatment with folinic acid (as calcium folinate) may be required in acute
toxicity.
3. The CSM has received reports of prescription and dispensing errors with
methotrexate, including fatalities. Attention should be paid to the strength of
methotrexate tablets prescribed and the frequency of dosing.
4. The label on prescribed/dispensed methotrexate should state the instructions
clearly, for example: ‘methotrexate 2.5mg tablets: (number of tablets) to be
taken as a single dose ONCE A WEEK on XXXDAY’.
5. Keep repeat prescriptions for methotrexate separate from others
6. In the treatment of non-cancer conditions (eg. rheumatology and
dermatology), methotrexate must be given once a week or once a month. Staff
that encounter methotrexate prescriptions must ensure the correct dosing
interval is given.
7. In patients who experience mucosal or gastrointestinal side effects with
methotrexate, folic acid 5mg each week (taken 48 hours after the methotrexate
dose) may be given. It may be given routinely to help reduce the frequency of
such side effects.
Methotrexate-induced mucositis or myelosuppression: folinic acid (given as
calcium folinate) is used to counteract the folate-antagonist action of
methotrexate and so facilitate recovery from methotrexate-induced mucositis or
myelosuppression.
8. Methotrexate and NSAIDs: if aspirin or other NSAIDs are given concurrently
the dose of methotrexate should be carefully monitored. Patients should be
advised to avoid self-medication with over-the-counter aspirin or ibuprofen.

13.05.03 Methotrexate 

Tablets 2.5mg, 10mg

02.05.02 Methyldopa 

Tablets 125mg, 250mg, 500mg

Note: Methyldopa is included for the treatment of hypertension in pregnancy only. 

04.04 Methylphenidate 
  • Tablet 5mg, 10mg, 20mg
  • Modified release tablet 18mg, 27mg, 36mg, 54mg (Xaggitin®XL)
06.03.02 Methylprednisolone Medrone®

Tablets 100mg

 

Unlicensed use for relapse in Multiple Sclerosis
Dose - Medrone tablets, 5 x 100mg (500mg) once daily for 5 days
Consultant Neurologist recommendation only.

See Fax sheet to ask GP to prescribe High Dose Oral Methylprednisolone in MS relapse. 

 

Notes:

  • Equivalent doses of glucocorticoid activity:5mg Prednisolone = Dexamethasone 750micrograms, Hydrocortisone 20mg, Methylprednisolone 4mg
  • Different preparations of dexamethasone contain different salts. Therefore, care is needed to ensure that patients receive equivalent doses when transferring from tablets to injections.
  • The equivalent doses are:1mg dexamethasone = 1.2mg dexamethasone phosphate = 1.3mg dexamethasone sodium phosphate

 

10.01.02.02 Methylprednisolone Acetate Depo-Medrone®

Depo-Medrone Injection (aqueous suspension), methylprednisolone acetate 40mg in 1ml, 80mg in 2ml, 120mg in 3ml vial

10.01.02.02 Methylprednisolone Acetate Depo-Medrone® with Lidocaine

Depo-Medrone with Lidocaine injection 40mg plus lidocaine 10mg in 1ml

20 Methylthioninium chloride Aguettant®
  • njection 1%, 10mL
  • Sterile solution 1%, 10mL
04.06 Metoclopramide 
  • Tablets 10mg
  • Syrup 5mg in 5mL
  • Injection 10mg in 2mL

 

Notes:

  • Traffic light status: Green for Palliative Care and Amber 2 for all other indications
  • For short term use (up to 5 days) in line with MHRA advice: Drug Safety Update (see link below).
  • Not recommended for patients under 20 years of age due to risk of dystonic reactions.
02.02.01 Metolazone 

Tablets 5mg

Notes:

  • Metolazone is a powerful diuretic, start with a dose of 2.5mg-5mg and monitor response closely.
  • Metolazone is included as an adjunct to loop diuretics in severe CCF and oliguria.
02.04 Metoprolol tartrate 
  • Tablets 50mg, 100mg
  • Injection 1mg/mL (5-mL amp) - Hospital only

Note: Metoprolol is a short-acting agent that may be used in Secondary Care post myocardial infarction (unlicensed indication).

05.01.11 Metronidazole 

Intravenous infusion 500mg / 100ml

05.01.11 Metronidazole 
  • Tablets 200mg, 400mg
  • Oral Suspension 200mg/5mL
  • Suppositories 500mg, 1 gram
07.02.02 Metronidazole Zidoval®

Gel 0.75%

13.10.01.02 Metronidazole topical 0.75% 

Gel, 0.75%    

20 Mexiletine 

Capsules 50mg and 200mg

Recommended dosage: initiate at 1.5 mg/kg and increase to 10 mg/kg (maximum daily dose of 600 mg)

Note: Approved for unlicensed use by hospital Consultant Neurologist only in congenital myotonia.

05.02.04 Micafungin Sodium Mycamine®

Mycamine® Intravenous Infusion, powder for reconstitution, 50mg, 100mg
vials

07.02.02 Miconazole Gyno-Daktarin®

Intravaginal cream 2%

 

12.03.02 Miconazole Daktarin®

Oral gel - Sugar free 2%     

12.03.02 Miconazole Daktarin®

Oral gel - Sugar free 2%     

13.10.02 Miconazole nitrate Daktarin®
  • Daktarin® Cream 2% (contains: butylated hydroxyanisole)   
04.08.02 Midazolam 

Important notes:

  • There are two formulations of buccal midazolam: Buccolam and Epistatus (see details below).
  • Always prescribe by brand to ensure that the correct product is supplied as they are not interchangeable.
  • There is a risk of harm if the patient receives the incorrect brand and strength of buccal midazolam.
    Buccolam® Oromucosal solution - midazolam (as hydrochloride) 5 mg/mL (Amber 1)
  1. 2.5mg in 0.5ml prefilled oral syringe
  2. 5 mg in 1ml prefillled oral syringe
  3. 7.5 mg in 1.5ml prefilled oral syringe
  4. 10 mg in 2ml prefilled oral syringe

Click here for information on how to administer Buccolam solution.

 

       Epistatus® Buccal solution - midazolam (as maleate) 10mg/mL (Red) - For use in hospital emergency trays only.

  1. Oromucosal solution in prefilled oral syringe
15.01.04.01 Midazolam pre-med
  • 2mg in 2mL amp

    5mg in 5mL amp

    10mg in 2mL amp

  • 10mg in 5mL amp
  • 100mg in 50mL vial
  • Epistatus 10mg in 1mL buccal liquid 5mL (U) "Consultant Initiation Only" (Amber 3)

Notes:

  • There have been reports of overdosage when high strength midazolam has been used for conscious sedation. Use should be restricted to general anaesthesia, intensive care, palliative care or other situations where the risk has been assessed.
  • Flumazenil must be kept in all departments that use IV or SC midazolam (NPSA/2008/RRR011).
  • Midazolam is a Schedule 3 CD and must be ordered in the CD order book. 
08.01.05 Midostaurin Rydapt®

Rydapt® Capsules 25mg

 

08.02.04 Mifamurtide Mepact®

Intravenous Infusion 4mg vial

 

07.01.02 Mifepristone 

Tablets 200mg

 

For termination of pregnancy, a single dose of mifepristone is followed by
administration of a prostaglandin (gemeprost or misoprostol [unlicensed]).

Guidelines from the Royal College of Obstetricians and Gynaecologists; The
Care of Women Requesting Induced Abortion (November 2011) include the
following [unlicensed] regimens for inducing medical abortion as detailed in the
BNF:

02.01.02 Milrinone 

Injection 1mg/mL (10mL amp) 

05.01.03 Minocycline 

Tablets 50mg 100mg

Capsules 50mg, 100mg

Modified release capsules 100mg

07.04.02 Mirabegron Betmiga®

Tablets modified release 25mg, 50mg

 

To be used third-line in line with agreed pathway: Pharmacotherapy for the
Management of LUTS in Males and Females (April 2019)

LUTS GP pathway: Pathway for the management of LUTS in Males and Females

Use as per NICE TA290: Overactive bladder - mirabegron (June 2013)

04.03.04 Mirtazapine 
  • Tablets 15mg, 30mg, 45mg
  • Orodispersible tablets 15mg, 30mg, 45mg
07.01.01 Misoprostol 

Tablets 200 micrograms

08.01.02 Mitomycin 

Injection, powder for reconstitution 20mg, 40mg vial

08.01.02 Mitoxantrone (Mitozantrone) 

Concentrate for IV infusion 20mg in 10ml, 30mg in 15ml

15.01.05 Mivacurium Mivacron®

 10mg in 5mL amp

04.03.02 Moclobemide 

Tablets 150mg, 300mg

Notes:

  • Patients should avoid consuming large amounts of tyramine-rich food (such as mature cheddar, yeast extracts, red wine and fermented soya bean products) and sympathomimetics (such as ephedrine, pseudoephedrine and phenylpropanolamine).
  • Please refer the patient to the patient information leaflet (PIL) supplied with the product for dietary restrictions. 
13.04 Mometasone Furoate 0.1% Elocon®
  •  0.1% ointment
  •  0.1% cream 
03.03.02 Montelukast 

Montelukast

  • Tablets 10mg (licensed >14 years)
  • Chewable tablets 4mg (licensed 2-5 years)
  • Chewable tablets 5mg (licensed 6-14 years)

Notes:

  • Montelukast is a leukotriene receptor antagonist (LTRA) for use in the management of asthma (not COPD or any other condition). It is licensed as an adjunctive therapy in the control of mild to moderate and exercise induced asthma and can be used from the age of 6 months.
  • Their possible role is as an add-on to, but not a substitute for, inhaled steroids. It is important to keep a small dose of inhaled corticosteroid.
  • LTRAs are not effective in all patients. A response to treatment is usually very quick; however, there can be some patients that are late responders. A therapeutic trial should be given for 4 weeks. If after this time no response is observed, discontinue treatment.
  • Montelukast can be used as an alternative at Step 2 of the British Thoracic Society asthma guidelines for children under five, or step 3 as an alternative to long acting beta2 agonist following no response for adults and children aged 5-12.
  • Patients in whom LTRAs may be particularly effective are those with aspirin sensitivity, a large exercise induced component to the symptoms, highly atopic eczema and rhinitis.
04.07.02 Morphine 

(Controlled Drug except for oral solution 10mg in 5mL)